System and process for continuous addition of cryoprotectant

Information

  • Patent Grant
  • 11889830
  • Patent Number
    11,889,830
  • Date Filed
    Friday, April 17, 2020
    4 years ago
  • Date Issued
    Tuesday, February 6, 2024
    3 months ago
  • Inventors
    • Busa; Domenic (DeForest, WI, US)
    • Botts; Michael (DeForest, WI, US)
    • Klas; Gary (DeForest, WI, US)
    • Parker; Johnathan (DeForest, WI, US)
  • Original Assignees
  • Examiners
    • Hobbs; Michael L
    • Abel; Lenora A
    Agents
    • NGUYEN TARBET LLC
Abstract
An integrated system and method for preparing sperm cells to improve their survivability during cryopreservation are described herein. The system features a vessel, a controlled dispenser, and a dispense tube. The dispense tube has a first end fluidly connected to the dispenser and a second end disposed inside the vessel. The second end can be submerged in the sperm cell fluid. The controlled dispenser may be a syringe pump that includes a syringe for containing a cryoprotectant and a pushing mechanism for displacing the syringe. The syringe pump is configured to discharge the cryoprotectant through the dispense tube and into the vessel, thereby dispensing the cryoprotectant into the sperm cell fluid. Mixing of the fluids is achieved using a shaker table agitation.
Description
BACKGROUND OF THE INVENTION
Field of the Invention

The present invention relates in general to processing and cryopreservation of semen. In particular, the present invention discloses systems and method featuring high-precision and continuous addition of a fluid with agitation to optimize cryopreservation of sperm cells.


Background Art

Cryopreservation of human spermatozoa involves the stabilization of sperm cells at cryogenic temperatures. This technology is commonly utilized in artificial insemination procedures or to preserve male fertility. During a cryopreservation procedure, a cryoprotectant is added to a sperm specimen to protect the sperm from freeze damage. A disadvantage of this procedure is that the uptake of the cryoprotectant imparts stress to the sperm cells, resulting in cell die-off. It is believed that a larger cryoprotectant to sperm cell concentration mismatch only increases this imparted stress. Past known solutions involve a drop-wise addition of cryoprotectant media via droplets breaking away from a suspended dispense tube, or step-wise addition comprising multiple discrete additions spaced minutes apart.


In drop-wise addition, a setup akin to a buret based titration is used. The cryo-protectant media (cryo-media) is added by drop over an extended period of time. In step-wise or bulk addition, the cryo-media is suspended in a vessel above the sperm sample. A stopcock attached to the vessel is used to start/stop flow. There is no deliberate control of the flow rate; instead, a mass balance is used to estimate the volume delivered. The addition of cryo-media is completed within minutes to read the desired total volume added. For example, the cryo-media may be added in three discrete bulk additions spaced 15 minutes apart. These procedures can still result in cell die-off; hence, there exists a need to reduce the rate of cell die off during the addition of a cryoprotectant media to sperm cells.


BRIEF SUMMARY OF THE INVENTION

It is an objective of the present invention to provide systems and methods that can mitigate the detrimental effects of cryopreservation on sperm integrity, as specified in the independent claims. Embodiments of the invention are given in the dependent claims. Embodiments of the present invention can be freely combined with each other if they are not mutually exclusive.


In some aspects, the present invention features an integrated cryopreservation system that can improve survivability and process yield of sperm cells. In an exemplary embodiment, the present invention may feature a dispensing system comprising a vessel, a controlled dispenser, and a dispense tube. The controlled dispenser may be configured to dispense the fluid through the dispense tube and into the vessel. A non-limiting example of the controlled dispenser is a syringe pump comprising a syringe for containing a fluid, such as the cryoprotectant, and a pushing mechanism for displacing the syringe plunger. The syringe pump may be configured to dispense the fluid through the dispense tube and into the vessel upon displacement of the syringe by the pushing mechanism. In some embodiments, the dispense tube has a first end fluidly connected to a discharge port of the controlled dispenser and a second end disposed inside the vessel. In one embodiment, the second end may be contacting a material contained within the vessel. The material contained within the vessel may be cells, such as sperm cells, in a sample medium (i.e. a liquid media that contains e.g. salts, sugars, buffers, proteins, antibiotics, lipids, anti-oxidants, etc.). In the case of sperm cells, the sperm cells can be sexed (i.e. post-processing) or unsexed (i.e. “conventional”). The system may also be used for other cell types, e.g. cell cultures, oocytes, and embryos. Alternatively, or in conjunction, the second end may be contacting an internal surface of the vessel.


According to some embodiments, the pushing mechanism may comprise a moveable pusher block, a motor operatively coupled to said pusher block, and a motor controller for controlling the motor. The pusher block and syringe may be arranged on a track and aligned such that the pusher block can press against a plunger of the syringe. The motor is configured to move the pusher block along the track in a direction that pushes the plunger into a barrel of the syringe, thereby displacing the syringe. Displacement of the syringe ejects the fluid contained in the barrel through the discharge port and into the dispense tube. The fluid exits the dispense tube through the second end and into the vessel.


In other aspects, the dispensing system may further comprise a mixer for mixing the contents in the vessel. In further embodiments, the dispensing system may further comprise one or more additional controlled dispensers, and a dispense tube fluidly connecting each controlled dispenser to the vessel. The additional dispensers can dispense the same or different fluids, such as cryoprotectants or gases, through their respective dispense tubes and into the vessel upon displacement by the pushing mechanisms.


In one embodiment, the controlled dispenser can continuously dispense the fluid. In a non-limiting example, the pushing mechanism may displace the syringe plunger such that the fluid is dispensed continuously from the second end of the dispense tube that is submerged in the sperm cells. In another embodiment, the controlled dispenser can continuously dispense the fluid such that droplet formation is prevented and the fluid is dispensed without being dripped into the vessel. In yet other embodiments, the controlled dispenser can dispense the fluid into the vessel at a flow rate that is less than or equal to a maximum flow rate, fmax, determined by the equation: fmax (ml/min)=0.0045*V, where V=volume of material in ml. In alternative embodiments, (for example, embodiments with a shorter dispense time of around 45 minutes) the maximum flow rate, fmax, may be determined by the equation: fmax (ml/min)=0.0056*V, where V=volume of material in ml. The maximum flow rate is dictated by the volume of cryoprotectant (which is in turn dictated by the measured amount of sample), which is added over a set amount of time. Typically, the addition time is about 60 minutes, but in some instances may be about 45 minutes. For larger samples, the volume of cryoprotectant needed will be larger, and thus the maximum flow rate will be larger. Thus, the addition time may be roughly constant, regardless of the sample size and the volume of cryoprotectant added, because the total flow rate may be scaled linearly with the volume.


According to other embodiments, the cryopreservation system of the present invention may be utilized in a method for preparing the biological specimens for cryopreservation. When implementing the syringe pump as the controlled dispenser, the method may comprise adding the cryoprotectant into the syringe, adding the biological specimen into a vessel, connecting the syringe to the vessel via a dispense tube, and displacing the syringe to dispense the cryoprotectant into the vessel at a desired flow rate, thereby adding the cryoprotectant to the biological specimen. In one embodiment, one end of the dispense tube may be contacting the biological specimen or an internal surface of the vessel. In some embodiments, the cryoprotectant is continuously dispensed into the vessel. In a preferred embodiment, the syringe is displaced such that droplet formation is prevented and the cryoprotectant is dispensed without being dripped into the vessel. In other embodiments, the cryoprotectant is dispensed into the vessel at a flow rate that is less than or equal to the maximum flow rate, fmax, determined by the previous equation.


One of the unique and technical features of the present invention is the continuous addition of the cryoprotectant to the specimen as compared to bulk or drop-wise addition. The same volume of cryoprotectant media, such as a glycerol-based cryoprotectant, can be added at a slow and continuous rate over a specified period of time. Another technical feature of the invention is the dispense tube submerged or contacting an internal surface of the vessel to enable low or soft impact addition of the cryoprotectant to the sperm cell solution. This feature can allow for gradual introduction of the cryoprotectant into the sperm cell solution in a manner that reduces cell stress. Yet another technical feature of the invention is the dilute addition of cryoprotectant in which the cryoprotectant enters the sperm cell fluid at a relatively low volume to reduce cytotoxity to local cells at or near the entry point. Without wishing to be limited by a particular theory or mechanism, it is believed that these technical features can reduce process risks and the rate of cell die off, thereby improving survivability and process yield of sperm cells. None of the presently known prior references or work has the unique inventive technical feature of the present invention.


In addition, the inventive technical feature of the present invention contributed to a surprising result. After extensive experimentation, it was unexpectedly found that through the cryopreservation preparation process, the survivability of cells increased by an average of 5% when using the submerged, continuous addition process in comparison to the step-wise addition process of three bulk additions spaced 15 minutes apart). The ratio of specimen volume to dispensed cryoprotectant volume was the same in both procedures. Furthermore, it was surprisingly found that cells prepared using the cryopreservation preparation process of the present invention had an 8% increase in survivability through the freeze/thaw procedure. Thus, the present invention was surprisingly able to increase the process yield of sperm cells, an outcome that one of ordinary skill in the art cannot simply predict or envision.


Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one of ordinary skill in the art. Additional advantages and aspects of the present invention are apparent in the following detailed description and claims.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

The patent application or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee


The features and advantages of the present invention will become apparent from a consideration of the following detailed description presented in connection with the accompanying drawings in which:



FIG. 1 shows a non-limiting embodiment of a dispensing or cryopreservation system of the present invention.



FIGS. 2A-2B show a non-limiting example of a controlled dispenser of the dispensing system. FIG. 2A depicts a partially displaced syringe pump and FIG. 2B depicts the syringe pump in a completely displaced position.



FIG. 3 shows another non-limiting embodiment of the cryopreservation system.



FIG. 4A is another non-limiting embodiment of the cryopreservation system. FIG. 4B shows an embodiment where multiple specimens can be processed simultaneously.



FIG. 5A shows an initial position of a syringe clamp. FIG. 5B shows a displaced position of the syringe clamp holding a syringe.



FIG. 6A shows an initial position of an inductive position sensor that is connected to the syringe clamp; a change in position is proportional to a change in voltage. FIG. 6B shows a displaced position of the sensor when the syringe clamp is holding the syringe.



FIG. 7 is a non-limiting schematic of a pumping mechanism of the invention.



FIGS. 8A-8C are non-limiting examples of process flow diagrams for dispensing a cryoprotectant according to the present invention.



FIG. 9 shows non-limiting examples of feed streams for dispensing the cryoprotectant.





DETAILED DESCRIPTION OF THE INVENTION

Following is a list of elements corresponding to a particular element referred to herein:

    • 100 system
    • 102 fluid or cryoprotectant
    • 104 biological specimen
    • 110 vessel
    • 112 internal surface of the vessel
    • 115 controlled dispenser, for example, a syringe pump
    • 120 syringe
    • 122 plunger
    • 124 barrel
    • 126 discharge port
    • 127 syringe clamp
    • 129 position sensor
    • 130 pushing mechanism
    • 132 pusher block
    • 134 motor
    • 136 motor controller
    • 138 track
    • 140 dispense tube
    • 142 first end of dispense tube
    • 144 second end of dispense tube
    • 150 mixer


As used herein, a “cryoprotectant” refers to a chemical substance that is added to a biological specimen in order to protect said specimen from freeze damage during cryopreservation. The term “cryoprotectant” may be used interchangeably with the terms “cryoprotectant media” or “cryo-media”. Examples of cryoprotectants include, but are not limited to, glycerol, ethylene glycol, dimethyl sulphoxide (DMSO), sucrose, trehalose, dextrose, fructose, tris(hydroxymethyl)aminomethane (TRIS), TRIS B, Tris-Fructose-Egg yolk-Glycerol (TFEG), citric acid, and 1,2-propanediol.


As used herein, the “controlled dispenser” refers to any device capable of delivering a fluid, such as cryoprotectant or gas, at a controlled flow rate. In some preferred embodiments, the dispenser is automated. In other embodiments, the dispenser may be non-automated. Non-limiting examples of controlled dispensers that may be used in accordance with the present invention include a syringe pump, mechanical pump, peristaltic pump, gravity pump, direct lift pump, microfluidic pump, centrifugal pump, compressor, gas regulator, or any positive-displacement pump. In some preferred embodiments, the dispenser may be any flow controller that can deliver fluid with similar accuracy as a syringe pump. In another example, the controlled dispenser may comprise a vessel that has with it a controlled pressure above the fluid and a downstream flow rate measurement. A simple feedback loop controls pressure based on flow rate error to a set point. Alternatively, a throttling valve may be implemented to control flow instead of controlling pressure on the fluid.


As used herein, the term “syringe” refers to a positive-displacement pump comprising a barrel and a moveable, e.g. slidable, plunger that can be inserted into the barrel. The plunger can include a seal that allows for the plunger to create a suction when the plunger is pulled away from the barrel, thereby drawing and trapping fluids in the barrel. Pushing the plunger into the barrel forces, e.g. discharges, the trapped fluids from the barrel. As used herein, the term “displace” and derivatives thereof when used in conjunction with syringe refer to the plunger being pushed into the barrel.


Referring now to FIG. 1, in one embodiment, the present invention features a dispensing system (100) comprising a vessel (110), a controlled dispenser (115), and a dispense tube. In some embodiments, the dispense tube (140) has a first end (142) fluidly connected to a discharge port (126) of the controlled dispenser and a second end (144) disposed inside the vessel (110). In one embodiment, the second end (144) may be contacting a material (104) contained within the vessel. In another embodiment, the second end (144) may be contacting an internal surface (112) of the vessel as shown in FIG. 3. Hereinafter, the controlled dispenser may be be exemplified by a syringe pump; however, it is to be understood that the controlled dispenser is not limited to a syringe pump and that it can be any device suited for delivering a fluid and controlling a flow rate thereof. In some embodiments, the syringe pump (115) may comprise a syringe (120) for containing a fluid (102) and a pushing mechanism (130) for displacing said syringe (120). The syringe pump (115) may be configured to dispense the fluid through the dispense tube (140) and into the vessel (110) upon displacement of the syringe (120) by the pushing mechanism (130).


According to some embodiments, the dispensing system (100) of the present invention may be utilized in cryopreservation procedure. For example, in one embodiment, the invention features a cryopreservation system (100) for dispensing a cryoprotectant (102) to a biological specimen (104). In some embodiments, the cryoprotectant (102) may comprise glycerol, ethylene glycol, dimethyl sulphoxide (DMSO), 1,2-propanediol, or any other suitable substance that can prevent damage to a biological specimen during freezing.


In one embodiment, the biological specimen (104) may comprise sperm cells. The sperm cells may comprise sex-sorted or gendered-skewed cells in which they predominantly contain an X-chromosome or a Y-chromosome. For example, the sperm cells may be sex-sorted to predominantly contain the X-chromosome so as to increase the likelihood that after insemination, the resulting fetus is a female. In another embodiment, the sperm cells may be unsorted. In other embodiments, the present invention is not limited to just sperm cells. Other types of specimens may be cryopreserved in accordance with the present invention. For example, the biological specimen may comprise tissues, stem cells, bone marrow, embryos, ova, oocytes, egg cells, amniotic fluid and umbilical cord, hepatocytes, blood cells, neuronal cells, organs, teeth, plant seeds, and microorganisms.


In one embodiment, the cryopreservation system (100) may comprise a vessel (110) for containing the biological specimen (104), a syringe pump (115) comprising a syringe (120) for containing the cryoprotectant (102) and a pushing mechanism (130) for displacing said syringe (120), and a dispense tube (140) having a first end (142) fluidly connected to a discharge port (126) of the syringe and a second end (144) disposed inside the vessel (110). The syringe pump (115) can dispense the cryoprotectant (102) through the dispense tube (140) and into the vessel (110) upon displacement of the syringe (120) by the pushing mechanism (130).


In some embodiments, the second end (144) may be in contact with an internal surface (112) of the vessel. For example, the second end (144) may be directly touching or positioned adjacent to the internal surface (112) of the vessel. In other embodiments, the second end (144) may be in contact with the biological specimen (104) when it is contained in the vessel (110). For instance, the second end (144) of the tube may be submerged in the biological specimen (104). In a preferred embodiment, the dispensed cryoprotectant (102) is prevented from being dripped into the vessel (110) by contacting the second end (144) of the tube with the biological specimen (104) or the internal surface (112) of the vessel. As used herein, the term “drip” and derivatives thereof refer to droplets breaking away from a suspended dispense tube.


In one embodiment, the internal surface (112) of the vessel can include an internal side surface or internal bottom surface of the vessel. In some embodiments, the vessel (110) may be a flask, a tube, or any container having sufficient volumetric capacity to hold the cryoprotectant (102) and biological specimen (104). For example, the vessel (110) may have a volumetric capacity ranging from about 20 ml to about 100 ml. In another embodiment, the capacity of the vessel (110) may range about 100 ml to about 250 ml or about 250 ml to about 500 ml. In yet another embodiment, the capacity of the vessel (110) may be greater than 500 ml. In other embodiments, the vessel (110) may be an enclosed or sealed container. As shown in FIG. 4A, the vessel can include a cap that has an input port for receiving the dispense tube (140), thus the cap allows for the vessel to be sealed while still providing access to the interior of the vessel. In some embodiments, the vessel (110) may be constructed from a rigid or semi-rigid material, such as glass or plastic. In further embodiments, the material may be opaque if the specimen is light sensitive, or substantially transparent for visibility into the vessel.


In one embodiment, if the second end (144) of the dispense tube is in contact with the biological specimen (104), the cryoprotectant (102) is directly added to the biological specimen (104). For instance, the second end (144) is submerged in the biological specimen (104) and cryoprotectant (102) as the cryoprotectant (102) is added into the vessel. In another embodiment, if the second end (144) of the dispense tube is in contact with an internal surface of the vessel but not in contact with the biological specimen (104), e.g. the vessel side wall, the cryoprotectant (102) may be added to the biological specimen (104) indirectly. As shown in FIG. 3, if the second end (144) is touching the vessel side wall, the cryoprotectant (102) flows along the vessel side wall as it is gradually added to the specimen. In either embodiment, droplet formation is broken up and the dispensed cryoprotectant (102) does not drip into the vessel (110).


Without wishing to limit the present invention to a particular mechanism, the syringe pump can control the rate of delivery of the cryoprotectant by precise displacement of the syringe plunger. In one embodiment, the addition rate is set programmatically as a function of the volume of cells. Since the batch size of sperm cells can vary greatly based on the number of cells received from an ejaculate, a wide range of addition volumes must be satisfied. In some embodiments, the volume of sperm cell fluid may range from about 1 ml to about 100 mL per semen sample. In preferred embodiments, the total volume cryo-media added may be about 10% to about 25% of the sperm cell sample volume. For example, a 25 ml semen sample may require about 20% of cryo-media, thus the cryo-media volume is about 5 ml.


In some embodiments, the total cryo-media addition spans about 60 minutes for each batch. In other embodiments, the addition time may range from about 45 to 90 minutes. Since the total cryo-media volume changes as a function of the volume of sperm cell fluid, the flow rate is set based on target volume divided by the addition time. In one embodiment, the flow rate of the dispensed fluid, also referred to as addition rate, may range from about 0.01 ml/min to about 1 ml/min. For example, the flow rate may be 0.017-0.333 mL/min. In another embodiment, the flow rate may be about 0.01 ml/min to about 0.05 ml/min or about 0.05 ml/min to about 0.1 ml/min. In a further embodiment, the flow rate may be about 0.1 ml/min to about 1 ml/min or greater than 1 ml/min. Continuing with the previous example, 5 ml of cryo-media may be continuously added to the 25 ml semen sample in a span of about 60 minutes, thus the cryo-media flow rate is about 0.083 ml/min.


As shown in FIGS. 2A-2B, the pushing mechanism (130) may comprise a moveable pusher block (132) disposed on a track (138). The pusher block (132) and syringe (120) may be arranged on the track (138) such that the pusher block (132) is aligned with the syringe (120). The pusher block (132) can move along the track (138) to press against the plunger (122) of the syringe. Referring to FIG. 5A-7, the pushing mechanism (130) further includes a motor (134) operatively coupled to the pusher block (132), and a motor controller (136) for controlling the motor (134). The motor (134) may be configured to move the pusher block (132) along the track (138) in a direction that pushes the plunger (122) into the barrel (124) of the syringe, thereby displacing the syringe (120) to eject the fluid (102), such as the cryoprotectant, contained in the barrel (124) through the discharge port (126) and into the dispense tube (102). The fluid (102) then exits the dispense tube (140) through the second end (144) and into the vessel.


As shown in FIG. 7, in some embodiments, an external processor, such as a computer, is used to control the entire system. The computer can execute a LabVIEW software to operate the system. For instance, upon receiving a user-input which can be entered via peripheral devices such as a mouse or keyboard, the computer transmits signals to the motor controller, which may be integrated into the syringe pump. In one embodiment, the motor controller (136) may comprise a processor and a memory operatively coupled to the processor. The memory can store a set of instructions that, when executed by the processor upon receiving the computer signals, causes the motor (134) to move the pusher block (132) along the track at a desired step size in the direction to displace the syringe (120). Thus, the cryoprotectant (102) is added to the biological specimen (104) at a desired flow rate.


In some embodiments, a continuous flow may refer to a smooth or non-discrete flow, a steady flow or an uninterrupted flow. In one embodiment, the pusher block (132) displaces the syringe (120) such that the cryoprotectant (102) is added to the biological specimen (104) at a continuous flow rate. For example, the motor moves the pusher block (132) at a specific step size such that the cryo-media flow rate is about 0.083 ml/min to continuously dispense 5 ml of cryo-media into a 25 ml semen sample in about 60 minutes as shown in FIG. 9, Feed A.


In other embodiments, the pusher block (132) can displace the syringe (120) such that the cryoprotectant (102) is added to the biological specimen (104) at a pulsed flow rate or an interrupted flow rate. A pulsed or interrupted flow rate refers to a flow rate in which there are discrete breaks in the flow; however, the flow is not drop wise. For example, 25% of the cryo-media volume is slowly and continuously added to the specimen in a span of 10 minutes, then paused for 5 minutes, and then repeated until the total volume of cryo-media is dispensed. As another example, 10% of the cryo-media volume is slowly and continuously added to the specimen in a span of 3-4 minutes, then paused for 2-3 minutes, and then repeated until the total volume of cryo-media is dispensed. Various non-limiting examples of pulsed or interrupted flow are shown in FIG. 9, Feeds B-G. In some embodiments, the pulsed flow rate may be a steady or constant flow rate, such as in Feeds B-D and F-G. Alternatively, the cryoprotectant may be fed at a varying pulsed flow rate, e.g. non-constant flow rate, over the course of the stream as illustrated in Feed E. In preferred embodiments, the cryoprotectant is dispensed in a manner and/or flow rate that inhibits droplet formation.


In one embodiment, the accuracy in the addition may be a function of the syringe inside bore diameter, if the linear step size of the syringe pump is fixed. To achieve the same accuracy across a range of addition volumes, by percentage of delivered volume to target volume, multiple sized syringes can be used. In some embodiments, the control software specifies the size of syringe based on the volume of sperm cells. If the wrong syringe is placed on the system, the amount of cryoprotectant media delivered could be significantly greater or less than specified. This error amounts to significant loss of cells through either initial cell die off in this process (over-delivery) or increased die off measured after thawing of cryopreserved cells (under-delivery). This risk is mitigated by implementing an inductive position sensor (128) to determine an outside diameter of the syringe placed on the system. As shown in FIGS. 5A-6B, the inductive position sensor (128) may be connected to a syringe clamp (127). When the syringe clamp is holding the syringe, the sensor is displaced and this change in the position of the sensor is proportional to a change in voltage, which correlates to the outer diameter of the syringe.


In preferred embodiments, the syringe used in accordance with the present invention should be biocompatible with the specimen. The syringe should be free off lubricants or other substance that could be detrimental to sperm cells. A non-limiting example of a syringe that is suitable for use with the present invention is a NORM-JECT luer lock syringe. In some embodiments, the volumetric capacity of the syringe may range from about 2 ml to about 50 ml. In one embodiment, the volumetric capacity of the syringe may be about 2 ml to about 5 ml. In another embodiment, the volumetric capacity of the syringe may be about 5 ml to about 20 ml. In yet another embodiment, the volumetric capacity of the syringe may be about 20 ml to about 50 ml. In further embodiments, the volumetric capacity of the syringe may be greater than 50 ml.


In other embodiments, the dispense tube may be constructed from a plastic, rubber, or silicone material. For example, the dispense tube may be made of PVC, DEHP-Free PVC, Tygon®, C-flex®, high density polyethylene, platinum cured silicone, or peroxide cured silicone. Moreover, the tubing material may be medical grade quality. In one embodiment, the dispense tube may be constructed of PEEK with 1/16″ OD, 0.020″ ID. An inner diameter of the tube can vary in size, ranging from about 0.01″ to about 0.1″. For example, the inner diameter may be 0.020″. The dispense tube can be a predetermined length or alternatively cut to a required length to sufficiently span the distance between the syringe and vessel. In some embodiments, the tubing material may be opaque. Alternatively, the tubing material may be substantially transparent to allow for visibility into the tube, for instance, to visualize any blockage in the tube. In other embodiments, the dispense tube may be flexible, semi-rigid, or rigid. Tubing expansion under pressure may increase error to the target delivery volume. To ensure accuracy, the tube can have a high OD/ID ratio with a rigid material, thereby reducing the risk of tubing expansion.


In the prior arts, a suspended vessel with a stopcock or a buret for addition has physical limitations that prohibits submersion of the dispense tip. For instance, the typical opening size of the vessel or the size of buret tip limits the ability to submerge the tip. In addition, by using a buret, which is typically made of brittle glass, physical contact with a vessel wall would place a bending force on the glass putting it at risk for fracture. Radial agitation of the vessel would only increase the fracture risk. In contrast, the dispense tube of the present invention allows for submersion of the dispense tip as well as agitation of the vessel.


Once sperm cells are packaged for sale, each lot is tested for bacteria. If bacteria levels are above a threshold, the batch is not sold as it could introduce a health risk. Furthermore, prevention of cell cross-contamination between batches is paramount. Thus, there is a need to prevent the cryo-media from becoming contaminated with bacteria and/or other cells. The present invention addresses these concerns by using a reusable or disposable fluid path. Without wishing to be limited to a particular theory or mechanism, the entire fluid path can eliminate contamination risks from bacteria and cross-contamination between different specimens, e.g. bull-bull.


In some embodiments, the dispense tubing and vessel may be reused through a cleaning and autoclave process. In other embodiments, the syringe may be discarded after use. In preferred embodiments, the dispense tubing is submerged into the fluid containing the sperm cells. By submerging the end of the dispense tubing instead of suspending it, the addition rate is governed by the syringe pump rather than the adhesion forces of suspending a droplet from the end of the dispense tubing.


In further embodiments, the system (100) may also include a mixer (150) for mixing the cryoprotectant (102) and the biological specimen (104) contained in the vessel (110). Without wishing to limit the present invention, the mixer (150) can prevent the biological specimen (104) from adhering to the internal surface (112) of the vessel. In one embodiment, the mixer (150) may be a shaker table. As an example, the shaker table may comprise a stationary base and a moveable platform that can support the vessel. As shown in FIG. 4A, the vessel (110) may be placed on the shaker table, which provides agitation to the fluid in the vessel, thereby mixing the cryoprotectant media into the fluid containing the sperm cells and reducing the local concentration at the end of the dispense tubing. The agitation rate of the shaker table may be programmatically set by rotational speed if the rotation radius is fixed by the equipment. While the shaker table can reduce contamination by eliminating contact with the contents of the vessel, other types of mixer equipment may be used with the system, such as a magnetic stir bar with stir plate or an overhead stirrer with an impeller, paddle, or blade. However, since there is a need to minimize shear forces on the sperm cells, which may be physically destroyed by a submerged rotating object, acoustic mixing may be implemented in accordance with the present invention. For example, acoustic mixing may involve sonication, which is agitation using sound energy.


As shown in FIG. 4B, in some embodiments, the dispense system (100) may be a multiple dispense system implementing a plurality of controlled dispensers and vessels to process multiple specimens simultaneously. In some embodiments, each vessel may contain its own specimen, which can be the same as or different from the specimens in the other vessels. Each vessel may be coupled to its own controlled dispenser, such as a syringe pump for example, to dispense its own a fluid. The fluid in each dispenser may be the same as or different from the fluid in the other dispensers. For example, one dispense system may be used to dispense glycerol into a semen sample and a second dispense system may be used to dispense glycerol into another semen sample of the same or different origin. As another example, one dispense system may be used to dispense glycerol into a tissue sample while a second dispense system may be used to dispense glycerol into a semen sample. In another embodiment, one dispense system may be used to dispense glycerol into an embryo specimen while a second dispense system may be used to dispense DMSO into a semen sample. The vessels can be placed on a single shaker table provided that the shaker table is capable of supporting and mixing a plurality of vessels. Alternatively, each vessel may have its own mixer.


In other embodiments, the multiple dispense system may implement a plurality of controlled dispensers, such as syringe pumps, fluidly coupled to a single vessel. This may allow for a shorter processing time by dispensing the cryoprotectant fluid from multiple dispensers. Alternatively, the dispensers can dispense various fluids, such as cryoprotectants or gases, into the single vessel simultaneously or sequentially. For instance, the dispense system may include multiple syringe pumps that dispense various fluids into a single vessel for vitrification of sperm cells. Each of the fluids can be dispensed at their own independent flow rates and timing. In one embodiment, the dispense system may include a syringe pump that dispenses a cryoprotectant and a second controlled dispenser that dispenses gas into a single vessel. Each of the fluids can be dispensed at their own independent flow rates and timing. In one example, the multiple dispense system may be configured to dispense two or more different medias that are added to the cells such that delivery is defined similar to a recipe. The flow rates of each media may be varied independently and/or the delivery between the medias may be coordinated, such as ramping the flow rate.


In some embodiments, the vessel may be equipped with a cap that can create an air-tight seal such that a gas can be added and contained within the vessel. The cap may include a port for receiving the gas, as well as other ports for receiving liquids. As an example, preparation of a specimen for in-vitro fertilization may require lower oxygen concentrations and/or some type of gas coverage in the vessel to improve survivability. In one embodiment, the vessel may be sealed and purged with argon, CO2 and/or nitrogen, which may be added via one or more ports, each coupled to its own pump or gas regulator. A separate exit port may be used to maintain atmospheric conditions and prevent pressure build-up in the vessel. In another embodiment, the process may operate under reduced pressure by coupling a port to a vacuum pump. In some embodiments, the cryo-media can be added with the gas via a separate input port and pump. In conjunction with or alternative to the syringe pumps, other types of pumps, such as a microfluidic pump, centrifugal pump, compressor, gas regulator, or another kind of positive-displacement pump, may be used in accordance with the present invention to dispense the cryo-media, gases, or other fluids.


According to some embodiments, the dispense systems of the present invention may implement a temperature ramp during the cryopreservation process. When preparing the biological specimen for cryopreservation, the specimen and cryoprotectant are preferably in a temperature controlled environment. In a preferred embodiment, the specimen and cryoprotectant are maintained at a temperature of about 5° C. Any deviation in temperature should not exceed ±2° C. For example, the temperature deviation may be ±1° C. In some embodiments, the entire system may be located in a temperature controlled room. If a dedicated cold room is not available, at least the syringe pump and vessel may be contained in a temperature controlled chamber, such as a cold box, so as to maintain constant temperature of the specimen and cryoprotectant. In another embodiment, the vessel and/or syringe may be jacketed with a heating/cooling device. Temperature feedback may be implemented via a thermocouple or thermistor, which can be submerged in the specimen solution or attached to the vessel.


According to some aspects, the systems described herein may be utilized in methods for dispensing a cryoprotectant to a biological specimen as shown in FIGS. 8A-8C. As a key initial step, the volume of cryoprotectant to be added may be determined, based on the amount of the sample, by pre-weighing the vessel, adding the sample, weighing the combined vessel and sample, and subtracting the masses to determine the mass of the sample, and calculating the proper volume of cryoprotectant. In one embodiment as shown in FIG. 8A, the method may comprise providing any one of the cryopreservation systems (100) described herein, fluidly coupling the cryoprotectant (102) to the controlled dispenser (115), adding the biological specimen (104) into the vessel (110), and activating the controlled dispenser (115) to continuously dispense the cryoprotectant (102) through the dispense tube (140) and into the vessel (110). In one embodiment, the controlled dispenser (115) comprises a syringe pump having a syringe and pumping mechanism as previously described herein. Preferably, the pushing mechanism (130) displaces the syringe (120) such that the cryoprotectant (102) is added to the biological specimen (104) continuously and at a desired flow rate. This can prevent droplet formation so that the cryoprotectant (102) is dispensed without being dripped into the vessel (110).


In another embodiment as shown in FIG. 8B, the method may comprise providing any one of the cryopreservation systems (100) described herein, adding a desired volume of cryoprotectant (102) into the syringe (120), adding the biological specimen (104) into the vessel (110), and activating the pushing mechanism (130) to displace the syringe (120). By displacing the syringe, the cryoprotectant (102) is dispensed through the dispense tube (140) and into the vessel (110). Preferably, the pushing mechanism (130) displaces the syringe (120) such that the cryoprotectant (102) is added to the biological specimen (104) at a flow rate that is less than or equal to a maximum flow rate, fmax, determined by the equation:

fmax (ml/min)=0.0045*V, where V=volume of the biological specimen in ml.

Returning to the previous example, the fmax for 5 ml of cryoprotectant to be dispensed into the 25 ml semen sample is calculated to be 0.11 ml/min. Thus, the cryoprotectant flow rate should be less than or equal to 0.11 ml/min with a minimum dispense time of about 45 minutes. The previous example flow rate of 0.083 ml/min and dispense time of 60 minutes are within these parameters.


Referring now to FIG. 8C, another embodiment of the method may comprise providing any one of the cryopreservation systems (100) described herein, adding a desired volume of cryoprotectant (102) into the syringe (120), adding the biological specimen (104) into the vessel (110), adjusting the second end (144) of the dispense tube such that said second end (144) is contacting the biological specimen (104) or an internal surface (112) of the vessel, and activating the pushing mechanism (130) to displace the syringe (120). By displacing the syringe, the cryoprotectant (102) is dispensed through the dispense tube (140) and into the vessel (110). Preferably, the pushing mechanism (130) displaces the syringe (120) such that the cryoprotectant (102) is added to the biological specimen (104) at a desired flow rate. More preferably, by contacting the second end (144) of the dispense tube with the internal surface (112) of the vessel or the biological specimen (104), the dispensed cryoprotectant (102) is prevented from being dripped into the vessel (110).


Consistent with the previous embodiments, the methods described herein may further include continuously or intermittently mixing the cryoprotectant (102) and the biological specimen (104) contained in the vessel (110). The cryoprotectant (102) and the biological specimen (104) may be mixed using any of the mixing equipment described herein. In further embodiments, the methods may also comprise adding one or more additional fluids to the vessel via activation of one or more additional controlled dispensers that are fluidly connected to the vessel, each dispenser containing one of the additional fluids. This method may utilize the multiple dispense system as previously described. In some embodiments, the one or more additional fluids may be cryoprotectants or gases. For example, a second fluid may be added to the vessel via activation of a second syringe pump which has a syringe containing the second fluid and is fluidly connected to the vessel.


Consistent with the previous embodiments, the methods described herein may further include weighing the vessel at the end of the addition to verify that the correct mass of cryoprotectant has been added. At this stage, if the mass is determined to be lower than it should be, additional cryoprotectant may be manually or automatically added in order to bring the total amount of cryoprotectant to the calculated amount. If the volume of the secondary, or manual, addition is large in comparison to the total calculated volume, it may be added in multiple sub-volume additions, with waiting time intervals between them. As a non-limiting example, if the volume of manual addition is up to 32% of the total volume the full remaining volume may be delivered in one addition. If the volume of the manual addition is 33-65% of the total volume, it may be divided into two equal quantities which are added with a 15 minute break between the additions. If the volume of the manual addition is equal or greater to 66% of the total volume, it may be divided into three equal quantities which are added with two 15 minute breaks between the additions.


In some aspects, the cryoprotectant may be toxic to the biological specimen, such as sperm cells, in high concentrations. Dispensing the cryoprotectant via bulk or drop-wise addition can deliver immediate high concentrations of the cryoprotectant to the cells that are closest to the entry location of the cryoprotectant prior to being diffused in the cell solution, thus resulting in cytotoxicity to the local cells. In other aspects, drop-wise addition of the cryoprotectant can lead to stress or physical damage due to the droplets striking the cells. Without wishing to limit the present invention to a particular theory or mechanism, the present invention allows for addition of the cryoprotectant in smaller volumes, via slow continuous flow, low-impact entry, and/or a determined flow rate, that reduce the local concentration so as to minimize cytotoxicity and cell stress.


In some embodiments, the dispensing system of the present invention may be used in a cold room or a large cold handling cabinet, so as to preserve sample viability. In an alternative embodiment, the system may be fit inside of a fridge or mini-fridge. Some components of the system, such as the frame, may need to be decreased in size so that the frame, main syringe pumps, and shaker table all fit inside the fridge or mini-fridge. In some embodiments, a secondary frame may be positioned outside of the fridge or mini-fridge (for example, on top of the fridge or mini-fridge) and components such as the computer, power supply, and monitor may be mounted to the secondary frame.


In some embodiments, the pump plunger may be designed so as to also act as a spring-loaded clamping piece that holds the syringes into the pump and block. Certain plungers and clamps may cause inconsistencies of measurement. As a non-limiting example, the sensor to tag distance of the unit may be altered, and may in turn cause the system to incorrectly identify what syringe was loaded into the pump. As such, specialty plungers may be advantageous. Additionally, specialty syringe pump covers may be advantageous so as to provide for safer cable management and easier maintenance removal.


EXAMPLE

The following is a non-limiting example of the present invention. It is to be understood that said example is not intended to limit the present invention in any way. Equivalents or substitutes are within the scope of the present invention.


The cryopreservation system was implemented and compared against a prior cryopreservation procedure. The cryoprotectant was added by the present system at a continuously flow rate, whereas the prior procedure involved three discrete additions spaced 15 minutes apart. The ratio of specimen volume to dispensed cryoprotectant volume was the same in both procedures. The present invention resulted in a 5% recovery of cells, thus the present invention provides, on average, 5% more cells than the prior procedure. Without wishing to limit the present invention to a particular theory or mechanism, the cryopreservation system reduced cell die off through cryopreservation freeze to thaw. Furthermore, the present invention resulted in an 8% increase in insemination dose in straws as compared to the prior procedure.


As used herein, the term “about” refers to plus or minus 10% of the referenced number.


Although there has been shown and described the preferred embodiment of the present invention, it will be readily apparent to those skilled in the art that modifications may be made thereto which do not exceed the scope of the appended claims. Therefore, the scope of the invention is only to be limited by the following claims. In some embodiments, the figures presented in this patent application are drawn to scale, including the angles, ratios of dimensions, etc. In some embodiments, the figures are representative only and the claims are not limited by the dimensions of the figures. In some embodiments, descriptions of the inventions described herein using the phrase “comprising” includes embodiments that could be described as “consisting essentially of” or “consisting of”, and as such the written description requirement for claiming one or more embodiments of the present invention using the phrase “consisting essentially of” or “consisting of” is met.


The reference numbers recited in the below claims are solely for ease of examination of this patent application, and are exemplary, and are not intended in any way to limit the scope of the claims to the particular features having the corresponding reference numbers in the drawings.

Claims
  • 1. A cryoprotectant dispensing system (100) comprising: a) a vessel (110);b) a controlled dispenser (115); andc) a dispense tube (140) having a first end (142) fluidly connected to a discharge port (126) of the dispenser and a second end (144) disposed inside the vessel (110); andd) a controller (136) operatively coupled to the controlled dispenser (115), the controller (136) comprising a processor and a memory operatively coupled to the processor;wherein the memory comprises instructions that, when executed by the processor, cause the controller (136) to actuate the controlled dispenser (115) to dispense a cryoprotectant (102) fluid through the dispense tube (140) and into the vessel (110) in a manner or flow rate such that droplet formation is prevented and the cryoprotectant (102) is dispensed without being dripped into the vessel (110), andwherein the second end (144) of the dispense tube is contacting an internal surface (112) of the vessel or submerged in a material (104) contained within the vessel so that the dispense cryoprotectant fluid (102) is further prevented from being dripped into the vessel (110).
  • 2. The system of claim 1, wherein the controlled dispenser (115) comprises a syringe pump including a syringe (120) for containing the fluid (102) and a pushing mechanism (130) for displacing said syringe (120), wherein the pushing mechanism (130) comprises a moveable pusher block (132), and a motor (134) operatively coupled to said pusher block (132), wherein the motor controller (136) for controlling the motor (134), wherein the syringe pump is configured to dispense the fluid upon displacement of the syringe (120) by the pushing mechanism (130).
  • 3. The system of claim 2, wherein the pusher block (132) and syringe (120) are arranged on a track (138), wherein the pusher block (132) is aligned with the syringe (120) such that the pusher block (132) can press against a plunger (122) of the syringe, wherein the motor (134) is configured to move the pusher block (132) along the track (138) in a direction that pushes the plunger (122) into a barrel (124) of the syringe, thereby displacing the syringe (120), wherein displacement of the syringe (120) ejects the fluid (102) contained in the barrel (124) through the discharge port (126) and into the dispense tube (140), wherein the fluid (102) exits the dispense tube (140) through the second end (144) and into the vessel (110).
  • 4. The system of claim 1, wherein the controlled dispenser (115) is configured to continuously dispense the fluid into the vessel (110).
  • 5. The system of claim 1, wherein the vessel (110) contains a biological specimen (104).
  • 6. The system of claim 1, further comprising a mixer (150).
  • 7. The system of claim 1, further comprising one or more additional controlled dispensers (115), and a dispense tube (140) fluidly connecting each controlled dispenser (115) to the vessel (110), wherein the one or more additional controlled dispensers (115) are configured to dispense the same or different fluid through the dispense tube (140) and into the vessel (110).
  • 8. A cryopreservation system (100) for dispensing a cryoprotectant (102) to a biological specimen (104), said system (100) comprising: a) a vessel (110) for containing the biological specimen (104);b) a syringe pump (115) comprising a syringe (120) for containing the cryoprotectant (102), and a pushing mechanism (130) for displacing said syringe (120); wherein the pushing mechanism (130) comprises a moveable pusher block (132), a motor (134) operatively coupled to said pusher block (132), and a motor controller (136) for controlling the motore (134), wherein the motor controller (136) comprises a processor, and a memory operatively coupled to the processor and storing a set of instructions that, when excuted by the processor, causes the motor (134) to move the pusher block (132) at a desired step size in the direction to displace the syringe (120) such that the cryoprotectant (102) is added to the biological specimen (104) at a desired flow rate; andc) a dispense tube (140) having a first end (142) fluidly connected to a discharge port (126) of the syringe and a second end (144) disposed inside the vessel (110) such that said second end (144) is contacting an internal surface (112) of the vessel or the biological specimen (104) when it is contained in the vessel (110);wherein the syringe pump (115) is configured to dispense the cryoprotectant (102) through the dispense tube (140) and into the vessel (110) upon displacement of the syringe (120) by the pushing mechanism (130),wherein by contacting the second end (144) of the tube with the internal surface (112) of the vessel or the biological specimen (104), droplet formation is prevented and the cryoprotectant (102) is dispensed without being dripped into the vessel (110).
  • 9. The system of claim 8, wherein the second end (144) of the tube is submerged in the biological specimen (104).
  • 10. The system of claim 8, wherein the pusher block (132) and syringe (120) are arranged on a track (138), wherein the pusher block (132) is aligned with the syringe (120) such that the pusher block (132) can press against a plunger (122) of the syringe, wherein the motor (134) is configured to move the pusher block (132) along the track (138) in a direction that pushes the plunger (122) into a barrel (124) of the syringe, thereby displacing the syringe (120), wherein displacement of the syringe (120) ejects the cryoprotectant (102) contained in the barrel (124) through the discharge port (126) and into the dispense tube (140), wherein the cryoprotectant (102) exits the dispense tube (140) through the second end (144) and into the vessel (110).
  • 11. The system of claim 8, wherein the pusher block (132) displaces the syringe (120) such that the cryoprotectant (102) is added to the biological specimen (104) at a continuous flow rate.
  • 12. The system of claim 8, wherein the pusher block (132) displaces the syringe (120) such that the cryoprotectant (102) is added to the biological specimen (104) at a pulsed flow rate.
  • 13. The system of claim 8 further comprising a mixer (150) for mixing the cryoprotectant (102) and the biological specimen (104) contained in the vessel (110), wherein the mixer (150) prevents the biological specimen (104) from adhering to the internal surface (112) of the vessel.
  • 14. The system of claim 13, wherein the mixer (150) is a shaker table, wherein the vessel (110) is placed on the shaker table, wherein shaking of the shaker table agitates the cryoprotectant (102) and the biological specimen (104).
  • 15. The system of claim 8 further comprising one or more additional syringe pumps (115), each comprising a syringe (120) containing another fluid and a pushing mechanism (130) for displacing said syringe (120), and a dispense tube (140) fluidly connecting each syringe (120) to the vessel (110), wherein the one or more additional syringe pumps (115) are configured to dispense the other fluid through the dispense tube (140) and into the vessel (110) upon displacement of the syringe (120) by the pushing mechanism (130).
  • 16. The system of claim 15, wherein the other fluid is a gas.
  • 17. A method for dispensing a cryoprotectant (102) to a biological specimen (104), said method comprising: a) fluidly coupling the cryoprotectant (102) to a controlled dispenser (115);b) adding the biological specimen (104) into a vessel (110);c) connecting the controlled dispenser (115) to the vessel (110) via a dispense tube (140), wherein a first end (142) of the dispense tube is fluidly connected to the controlled dispenser (115), and a second end (144) of the dispense tube is disposed inside the vessel (110) such that said second end (144) is contacting the biological specimen (104) or an internal surface (112) of the vessel;andd) dispensing the cryoprotectant (102) into the vessel (110) at a desired flow rate via the controlled dispenser (115), thereby adding the cryoprotectant (102) to the biological specimen (104);wherein by contacting the second end (144) of the dispense tube with the internal surface (112) of the vessel or the biological specimen (104), droplet formation is prevented and the cryoprotectant (102) is dispensed without being dripped into the vessel (110).
CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a non-provisional application and claims benefit of U.S. Patent Application No. 62/835,676, filed Apr. 18, 2019, the specification of which is incorporated herein in their entirety by reference.

US Referenced Citations (341)
Number Name Date Kind
3390449 Fox Jul 1968 A
3649829 Randolph Mar 1972 A
3661460 Elking et al. May 1972 A
3710933 Fulwyler et al. Jan 1973 A
3764901 Kachel Oct 1973 A
3791517 Friedman Feb 1974 A
3863962 Thomas et al. Feb 1975 A
4175662 Zold Nov 1979 A
4325706 Gershman et al. Apr 1982 A
4395397 Shapiro Jul 1983 A
4409106 Furuta et al. Oct 1983 A
4424132 Iriguchi Jan 1984 A
4660971 Sage et al. Apr 1987 A
4667830 Nozaki, Jr. et al. May 1987 A
4765737 Harris et al. Aug 1988 A
4885473 Shofner et al. Dec 1989 A
4919817 Schoendorfer et al. Apr 1990 A
4983038 Ohki et al. Jan 1991 A
5007732 Ohki et al. Apr 1991 A
5030002 North, Jr. Jul 1991 A
5100627 Buican et al. Mar 1992 A
5125749 Eugers et al. Jun 1992 A
5135759 Johnson Aug 1992 A
5180065 Touge et al. Jan 1993 A
5194909 Tycko Mar 1993 A
5229297 Schnipelsky et al. Jul 1993 A
5483469 Van den engh et al. Jan 1996 A
5491550 Dabbs Feb 1996 A
5620857 Weetall et al. Apr 1997 A
5674743 Ulmer Oct 1997 A
5689109 Schultze Nov 1997 A
5752606 Wilson et al. May 1998 A
5800690 Chow et al. Sep 1998 A
5837115 Austin et al. Nov 1998 A
5849178 Holm et al. Dec 1998 A
5858187 Ramsey et al. Jan 1999 A
5879625 Rosianiec et al. Mar 1999 A
5966457 Lemelson Oct 1999 A
5985216 Rens et al. Nov 1999 A
6008010 Greenberger et al. Dec 1999 A
6053856 Hlavinka Apr 2000 A
6071442 Dean et al. Jun 2000 A
6146897 Cohenford et al. Nov 2000 A
6159739 Weigl et al. Dec 2000 A
6159749 Yagang et al. Dec 2000 A
6171865 Weigl et al. Jan 2001 B1
6185664 Jeddeloh Feb 2001 B1
6213151 Jacobson et al. Apr 2001 B1
H1960 Conrad et al. Jun 2001 H
6368871 Christel et al. Apr 2002 B1
6416190 Grier et al. Jul 2002 B1
6416959 Giuliano et al. Jul 2002 B1
6432630 Blankenstein Aug 2002 B1
6451264 Bhullar et al. Sep 2002 B1
6494230 Chow Dec 2002 B2
6506609 Wada Jan 2003 B1
6519032 Kuebler et al. Feb 2003 B1
6519954 Prien et al. Feb 2003 B1
6524860 Seidel et al. Feb 2003 B1
6540895 Spence et al. Apr 2003 B1
6549275 Cabuz et al. Apr 2003 B1
6592821 Wada et al. Jul 2003 B1
6637463 Lei et al. Oct 2003 B1
6674525 Bardell et al. Jan 2004 B2
6727451 Fuhr et al. Apr 2004 B1
6808075 Bohm et al. Oct 2004 B2
6833542 Wang et al. Dec 2004 B2
6838056 Foster Jan 2005 B2
6841388 Dukor et al. Jan 2005 B2
6853654 Mcdonald et al. Feb 2005 B2
6877528 Gilbert et al. Apr 2005 B2
6944324 Tran et al. Sep 2005 B2
6976590 Deshpande et al. Dec 2005 B2
7029430 Hlavinka et al. Apr 2006 B2
7069943 Gilbert et al. Jul 2006 B2
7092154 Yasuda et al. Aug 2006 B2
7104405 Böhm et al. Sep 2006 B2
7208265 Schenk Apr 2007 B1
7195920 Seidel et al. May 2007 B2
7241988 Gruber et al. Jul 2007 B2
7276701 Lendl Oct 2007 B2
7298478 Gilbert et al. Nov 2007 B2
7300803 Lin et al. Nov 2007 B2
7311476 Gilbert et al. Dec 2007 B2
7312085 Chou et al. Dec 2007 B2
7355696 Mueth et al. Apr 2008 B2
7355699 Gilbert et al. Apr 2008 B2
7466734 Day et al. Dec 2008 B1
7472794 Oakey et al. Jan 2009 B2
7482577 Gruber et al. Jan 2009 B2
7492522 Gilbert et al. Feb 2009 B2
7524681 Wolf et al. Apr 2009 B2
7569788 Deshpande et al. Aug 2009 B2
7576861 Gilbert et al. Aug 2009 B2
7584857 Böhm et al. Sep 2009 B2
7611309 Gilbert et al. Nov 2009 B2
7670471 Quake et al. Mar 2010 B2
7697576 Maier et al. Apr 2010 B2
7760351 Cox et al. Jul 2010 B2
7820425 Schenk Oct 2010 B2
7826509 Belkin et al. Nov 2010 B2
7956328 Sundaram et al. Jun 2011 B2
7963399 Böhm et al. Jun 2011 B2
7997831 Gilbert et al. Aug 2011 B2
8032200 Tearney et al. Oct 2011 B2
8080422 Neas et al. Dec 2011 B2
8123044 Johnson et al. Feb 2012 B2
8149402 Rich Apr 2012 B2
8158122 Hampson et al. Apr 2012 B2
8173001 Quake et al. May 2012 B2
8174394 Ridder et al. May 2012 B2
8198092 Durack et al. Jun 2012 B2
8206987 Durack et al. Jun 2012 B2
8209987 Hautman et al. Jul 2012 B2
8210209 Gilbert et al. Jul 2012 B2
8277764 Gilbert et al. Oct 2012 B2
8388822 Quake et al. Mar 2013 B2
8408399 Böhm et al. Apr 2013 B2
8502148 Wagner et al. Aug 2013 B2
8529161 Gilbert et al. Sep 2013 B2
8563325 Bartsch et al. Oct 2013 B1
8567608 Deshpande et al. Oct 2013 B2
8569069 Durack Oct 2013 B2
8623295 Gilbert et al. Jan 2014 B2
8727131 Deshpande et al. May 2014 B2
8731860 Charles et al. May 2014 B2
8941062 Wagner et al. Jan 2015 B2
8961904 Xia et al. Feb 2015 B2
8964184 Gilbert et al. Feb 2015 B2
8981298 Wagner et al. Mar 2015 B2
9000357 Mueth et al. Apr 2015 B2
9003869 Wagner et al. Apr 2015 B2
9011797 Gilbert et al. Apr 2015 B2
9109195 Zimmermann et al. Aug 2015 B2
9140690 Mueth et al. Sep 2015 B2
9255874 Sharpe et al. Feb 2016 B2
9260693 Johnson et al. Feb 2016 B2
9335247 Sharpe et al. May 2016 B2
9335295 Mueth et al. May 2016 B2
9339850 Deshpande et al. May 2016 B2
9365822 Seidel et al. Jun 2016 B2
9377400 Wagner et al. Jun 2016 B2
9446912 Gilbert et al. Sep 2016 B2
9485984 Burbank Nov 2016 B2
9550215 Deshpande et al. Jan 2017 B2
9588100 Appleyard et al. Mar 2017 B2
9618442 Sharpe et al. Apr 2017 B2
9683922 Wagner et al. Jun 2017 B2
D791338 Morkos et al. Jul 2017 S
9752976 Gilbert et al. Sep 2017 B2
9781918 Zimmermann Oct 2017 B2
9802767 Gilbert et al. Oct 2017 B2
9823252 Gilbert et al. Nov 2017 B2
9835552 Wagner Dec 2017 B2
D815754 Morkos et al. Apr 2018 S
9943847 Gilbert et al. Apr 2018 B2
9964968 Sharpe et al. May 2018 B2
10025322 Ofstrom et al. Jul 2018 B2
10029283 Deshpande et al. Jul 2018 B2
10175159 Wagner et al. Jan 2019 B2
10180388 Wagner Jan 2019 B2
10216144 Mueth et al. Feb 2019 B2
10315194 Akiyama et al. Jun 2019 B2
11187224 Xia et al. Nov 2021 B2
11193879 Wagner et al. Dec 2021 B2
11243494 Mueth et al. Feb 2022 B2
20020027649 Chudner Mar 2002 A1
20020042042 Fahy Apr 2002 A1
20020058332 Quake et al. May 2002 A1
20020106716 Leboeuf et al. Aug 2002 A1
20020115208 Mitchell et al. Aug 2002 A1
20020176069 Hansen et al. Nov 2002 A1
20020198928 Bukshpan et al. Dec 2002 A1
20030007894 Wang et al. Jan 2003 A1
20030032204 Walt et al. Feb 2003 A1
20030047676 Grier et al. Mar 2003 A1
20030054365 Xu et al. Mar 2003 A1
20030054558 Kurabayashi et al. Mar 2003 A1
20030068646 Singh et al. Apr 2003 A1
20030113709 Alivisatos et al. Jun 2003 A1
20030175944 Yang et al. Sep 2003 A1
20030175980 Hayenga et al. Sep 2003 A1
20030186426 Brewer et al. Oct 2003 A1
20040043506 Haussecker et al. Mar 2004 A1
20040079893 Dietz et al. Apr 2004 A1
20040089798 Gruber et al. May 2004 A1
20040144648 Jacobson et al. Jul 2004 A1
20040161772 Bohm et al. Aug 2004 A1
20040166504 Rossier et al. Aug 2004 A1
20040206399 Heller et al. Oct 2004 A1
20040217297 Moses et al. Nov 2004 A1
20040229349 Daridon Nov 2004 A1
20040266022 Sundararajan et al. Dec 2004 A1
20050037471 Liu et al. Feb 2005 A1
20050061962 Mueth et al. Mar 2005 A1
20050103690 Kawano et al. May 2005 A1
20050112541 Durack et al. May 2005 A1
20050121604 Mueth et al. Jun 2005 A1
20050123450 Gilbert Jun 2005 A1
20050124869 Hefti et al. Jun 2005 A1
20050148085 Larsen Jul 2005 A1
20050153354 Gilmanshin Jul 2005 A1
20050190372 Dogariu Sep 2005 A1
20050196876 Chan et al. Sep 2005 A1
20050207940 Butler et al. Sep 2005 A1
20050207943 Puzey Sep 2005 A1
20060013270 Yumoto et al. Jan 2006 A1
20060035273 Quake et al. Feb 2006 A1
20060043301 Mantele et al. Mar 2006 A1
20060058167 Regusa et al. Mar 2006 A1
20060078888 Griffiths Apr 2006 A1
20060105453 Brenan et al. May 2006 A1
20060152707 Kanda Jul 2006 A1
20060170912 Mueth et al. Aug 2006 A1
20060252047 Ekstrom et al. Nov 2006 A1
20060257089 Mueth et al. Nov 2006 A1
20060263829 Evans et al. Nov 2006 A1
20070009386 Padmanabhan et al. Jan 2007 A1
20070078348 Holman Apr 2007 A1
20070114172 Mueth et al. May 2007 A1
20070128082 Yang et al. Jun 2007 A1
20070207551 Glensbjerg Sep 2007 A1
20070247620 Koo Oct 2007 A1
20070248958 Jovanovich et al. Oct 2007 A1
20070255362 Levinson et al. Nov 2007 A1
20080003685 Goix et al. Jan 2008 A1
20080014574 Viator et al. Jan 2008 A1
20080021674 Puskas Jan 2008 A1
20080069733 Maltezo et al. Mar 2008 A1
20080144037 Mueth et al. Jun 2008 A1
20080166188 Gilbert et al. Jul 2008 A1
20080195020 Cabuz et al. Aug 2008 A1
20080213821 Liu et al. Sep 2008 A1
20080248966 Hansen et al. Oct 2008 A1
20080261295 Butler et al. Oct 2008 A1
20080292555 Ye et al. Nov 2008 A1
20080299013 Trieu et al. Dec 2008 A1
20080309919 Birmingham et al. Dec 2008 A1
20080311005 Kim et al. Dec 2008 A1
20090004652 Rubin et al. Jan 2009 A1
20090029870 Ward et al. Jan 2009 A1
20090032449 Mueth et al. Feb 2009 A1
20090042241 Yu-Chong et al. Feb 2009 A1
20090051912 Salazar et al. Feb 2009 A1
20090114285 Hashimoto et al. May 2009 A1
20090125242 Choi et al. May 2009 A1
20090141279 Hillmer Jun 2009 A1
20090156932 Zharov Jun 2009 A1
20090170149 Viator et al. Jul 2009 A1
20090176271 Durack et al. Jul 2009 A1
20090201504 Ho et al. Aug 2009 A1
20090225319 Lee et al. Sep 2009 A1
20090281250 DeSimone et al. Nov 2009 A1
20090290156 Popescu et al. Nov 2009 A1
20100044570 McGill et al. Feb 2010 A1
20100068723 Jovanovich et al. Mar 2010 A1
20100079516 Nakazawa Apr 2010 A1
20100167336 Son et al. Jul 2010 A1
20100171954 Quake et al. Jul 2010 A1
20100216208 Mueth et al. Aug 2010 A1
20100248362 Durack et al. Sep 2010 A1
20100330693 Chapin et al. Dec 2010 A1
20110001963 Durack Jan 2011 A1
20110003303 Pagano et al. Jan 2011 A1
20110003324 Durack Jan 2011 A1
20110003325 Durack Jan 2011 A1
20110003330 Durack Jan 2011 A1
20110008764 Silva et al. Jan 2011 A1
20110008767 Durack Jan 2011 A1
20110008817 Durack Jan 2011 A1
20110008818 Durack Jan 2011 A1
20110075928 Jeong et al. Mar 2011 A1
20110076712 Gilligan et al. Mar 2011 A1
20110090500 Hu et al. Apr 2011 A1
20110096327 Papautsky et al. Apr 2011 A1
20110190146 Boehm et al. Aug 2011 A1
20110223654 Holman et al. Sep 2011 A1
20110256523 Mendele et al. Oct 2011 A1
20110263747 Doyle et al. Oct 2011 A1
20110294139 Takeda Dec 2011 A1
20120009619 Gilbert et al. Jan 2012 A1
20120028366 Krager et al. Feb 2012 A1
20120033220 Kotidis et al. Feb 2012 A1
20120033697 Goyal et al. Feb 2012 A1
20120081709 Durack Apr 2012 A1
20120082362 Diem et al. Apr 2012 A1
20120107805 Neas et al. May 2012 A1
20120122084 Wagner et al. May 2012 A1
20120138152 Villamuel et al. Jun 2012 A1
20120183947 Mueth et al. Jul 2012 A1
20120196356 Wagner et al. Aug 2012 A1
20120199741 Wagner et al. Aug 2012 A1
20120199742 Wagner et al. Aug 2012 A1
20120202237 Sedoglavich et al. Aug 2012 A1
20120202277 Wagner et al. Aug 2012 A1
20120202278 Wagner et al. Aug 2012 A1
20120204628 Wagner et al. Aug 2012 A1
20120225474 Wagner et al. Sep 2012 A1
20120225475 Wagner et al. Sep 2012 A1
20120273054 Lou et al. Nov 2012 A1
20120287419 Sharpe et al. Nov 2012 A1
20120295263 Cantor et al. Nov 2012 A1
20120307244 Lou et al. Nov 2012 A1
20130121877 Ono May 2013 A1
20130164731 Cimino Jun 2013 A1
20130164773 Bardell et al. Jun 2013 A1
20130200277 Li et al. Aug 2013 A1
20130224843 Evans et al. Aug 2013 A1
20130252237 Wagner Sep 2013 A1
20130295602 Fowler Nov 2013 A1
20130313170 Bohm et al. Nov 2013 A1
20140033808 Ding et al. Feb 2014 A1
20140050540 Gilbert et al. Feb 2014 A1
20140091014 Wagner et al. Apr 2014 A1
20140224710 Di Carlo et al. Aug 2014 A1
20140273192 Sharpe Sep 2014 A1
20140287243 Weber et al. Sep 2014 A1
20140318645 Koksal Oct 2014 A1
20140339446 Yamamoto et al. Nov 2014 A1
20140361148 Popescu et al. Dec 2014 A1
20150064694 Sadri Mar 2015 A1
20150114093 Appleyard et al. Apr 2015 A1
20150192511 Wagner et al. Jul 2015 A1
20150198517 Simpson et al. Jul 2015 A1
20150276588 Marshall et al. Oct 2015 A1
20160004060 Simpson et al. Jan 2016 A1
20160123858 Kapur et al. May 2016 A1
20160199835 Tachibana et al. Jul 2016 A1
20170016813 Wagner et al. Jan 2017 A1
20170181425 Burbank Jun 2017 A1
20170333902 Masaeli Nov 2017 A1
20180266937 de Wagenaar et al. Sep 2018 A1
20190025212 Evans Jan 2019 A1
20190040356 Durack et al. Feb 2019 A1
20190071725 Roti-Roti et al. Mar 2019 A1
20190160439 Muto et al. May 2019 A1
20190187044 Appleyard et al. Jun 2019 A1
20190390164 Morjal et al. Dec 2019 A1
20200070152 Kasai et al. Mar 2020 A1
20220025443 Korani et al. Jan 2022 A1
20220026341 Appleyard et al. Jan 2022 A1
Foreign Referenced Citations (110)
Number Date Country
1341328 Dec 2001 CA
2125369 Dec 1992 CN
1482369 Mar 2004 CN
1886315 Dec 2006 CN
101189504 May 2008 CN
203952247 Nov 2014 CN
105532638 May 2016 CN
205323294 Jun 2016 CN
105831105 Aug 2016 CN
206014950 Mar 2017 CN
207418761 May 2018 CN
109221081 Jan 2019 CN
109497040 Mar 2019 CN
109517787 Mar 2019 CN
0057907 Aug 1982 EP
0282994 Sep 1988 EP
0679325 Jul 1994 EP
0471758 Sep 1996 EP
2798557 Mar 2001 FR
502971 May 1939 GB
2507959 May 2014 GB
57-131451 Aug 1982 JP
58090513 May 1983 JP
S 64-26125 Jan 1989 JP
64074451 Mar 1989 JP
02105041 Apr 1990 JP
03297385 Dec 1991 JP
H0526799 Feb 1993 JP
06265452 Sep 1994 JP
06327494 Nov 1994 JP
07024309 Jan 1995 JP
07286953 Oct 1995 JP
2552582 Nov 1996 JP
H10512952 Dec 1998 JP
H11508182 Jul 1999 JP
2000146819 May 2000 JP
2000512541 Sep 2000 JP
2001504936 Apr 2001 JP
2002503334 Jan 2002 JP
2002153260 May 2002 JP
2003106980 Apr 2003 JP
2003515738 May 2003 JP
2004093553 Mar 2004 JP
2005502482 Jan 2005 JP
2005530986 Oct 2005 JP
2006524054 Oct 2006 JP
2007-514522 Jun 2007 JP
2007148981 Jun 2007 JP
2007514522 Jun 2007 JP
2007515936 Jun 2007 JP
2008533440 Aug 2008 JP
2008261295 Oct 2008 JP
2009085872 Apr 2009 JP
2009115672 May 2009 JP
2010117197 May 2010 JP
2010151777 Jul 2010 JP
2010190680 Sep 2010 JP
2011145185 Jul 2011 JP
2014503195 Feb 2014 JP
WO9622521 Jul 1996 WO
WO9700442 Jan 1997 WO
WO1997030338 Aug 1997 WO
WO9739338 Oct 1997 WO
WO9747390 Dec 1997 WO
WO9810267 Mar 1998 WO
WO9939223 Aug 1999 WO
WO20000070080 Nov 2000 WO
WO0118400 Mar 2001 WO
WO0131315 May 2001 WO
WO2001040766 Jun 2001 WO
WO0185913 Nov 2001 WO
WO2002006778 Jan 2002 WO
WO200241906 May 2002 WO
WO2002081183 Oct 2002 WO
WO02087792 Nov 2002 WO
WO03024163 Mar 2003 WO
WO03062867 Jul 2003 WO
WO03078065 Sep 2003 WO
WO2003078065 Sep 2003 WO
WO2004012133 Feb 2004 WO
WO2004029221 Apr 2004 WO
WO2004043506 May 2004 WO
WO2004088283 Oct 2004 WO
WO20040088283 Oct 2004 WO
WO2005023391 Mar 2005 WO
WO2005075629 Aug 2005 WO
WO20050075629 Aug 2005 WO
WO2006119806 Nov 2006 WO
WO20060119806 Nov 2006 WO
WO2007008495 Jan 2007 WO
WO2007133710 Nov 2007 WO
WO2008114458 Sep 2008 WO
WO2008126064 Oct 2008 WO
WO2008130977 Oct 2008 WO
WO2009032449 Mar 2009 WO
WO2009134395 Nov 2009 WO
WO2010129441 Nov 2010 WO
WO2012068287 May 2012 WO
WO2012112641 Aug 2012 WO
WO20120112641 Aug 2012 WO
WO20130018273 Feb 2013 WO
WO2013173446 Nov 2013 WO
WO2005037471 Sep 2014 WO
2015038494 Mar 2015 WO
WO2015063552 May 2015 WO
WO2018047011 Mar 2018 WO
WO2018047011 May 2018 WO
WO2018151680 Aug 2018 WO
WO2020092321 May 2020 WO
WO2020182193 Sep 2020 WO
Non-Patent Literature Citations (246)
Entry
USPTO, “Final Office Action,” issued in connection with U.S. Appl. No. 16/741,608, dated Oct. 21, 2021, 11 pages.
Trial Transcript, Sep. 5, 2019 (a.m.); ABS Global, Inc. v. Inguran, LLC d/b/a Sexing Technologies, Case Nos. 17-cv-446 and 14-cv-503, United States District Court for the Western District of Wisconsin.
Brief in Support of ABS Global, Inc. and Genus PLC's Rule 50(8) Motion for Judgment as a Matter of Law and Rule 59 Motion for a New Trial, ABS Global, Inc. v. Inguran, LLC d/b/a Sexing Technologies, Case No. 14-cv-503, United States District Court for the Western District of Wisconsin. Filed Sep. 2, 2016.
Inguran, LLC and XY, LLC's Response to ABS Global, Inc. and Genus PLC's Rule 50(8) Motion Fof Judgment as a Matter of Law and Rule 59 Motion for New Trial, pp. 9-28, 33-36, 73-74. Filed Sep. 23, 2016.
ST's Response to ABS's Renewed Motion for Judgment as a Matter of Law That the Asserted Claims of the '987 Patent Are Invalid for Lack of Enablement and, in the Alternative, for a New Trial, ABS Global, Inc. v. Inguran, LLC d/b/a Sexing Technologies, Case No. 14-cv-503, United States District Court for the Western District of Wisconsin. Filed: Jul. 24, 2020.
Clinical Laboratory Instruments and In Vitro Diagnostic Reagents, Personnel Department of the State Food and Drug Administration, et al., pp. 17-21, China Medical Science and Technology Publishing House, Oct. 31, 2010).
DiCarlo “Continuous inertial focusing, ordering, and separation of particles in microchannels” BioMEMS Resource Center, Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Nov. 27, 2007, PNAS, 18892-18897, vol. 104, No. 48.
DiCarlo “Equilibrium Separation and Filtration of Particles Using Differential Inertial Focusing” BioMEMS Resource Center, Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Anal Chem 2008, 8, 2204-2211.
DiCarlo “Inertial Microfluidics: High-Throughput Focusing and Separation of Cells and Particles” BioMEMS Resource Center, Center for Engineering in Medicine, Massachusetts General Hospital, Twelfth International Conference on Miniaturized Systems for Chemistry and Life Sciences, Oct. 12-16, 2008, San Diego, California, USA.
Altendorf et al., “Results Obtained Using a Prototype Microfluidics-Based Hematology Analyzer,” in Proceedings of the microTAS 1998 Symposium, 73-76 (Oct. 1998).
Nieuwenhuis et al., “Particle-Shape Sensing-Elements for Integrated Flow Cytometer,” in Proceedings of the microTAS 2001 Symposium, 357-358 (Oct. 21, 2001).
Nieuwenhuis et al. “Virtual Flow Channel: A Novel Micro-fluidics System with Orthogonal, Dynamic Control of Sample Flow Dimensions,” in Proceedings of the microTAS 2002 Symposium, vol. 1, 103-105 (Nov. 3, 2002).
Nieuwenhuis, J., et al. “Integrated flow-cells for novel adjustable sheath flows.” Lab Chip, 2003, 3, 56-61 (Mar. 2003.
Shoji, S., et al. “Design and fabrication of micromachined chemical/biochemical systems.” Riken Rev., vol. 36, pp. 8-11, 2001.
Lin, C., et al. “A Novel Microflow Cytometer with 3-dimensional Focusing Utilizing Dielectrophoretic and Hydrodynamic Forces.” The Sixteenth Annual International Conference on Micro Electro Mechanical Systems, 2003. MEMS-03 Kyoto IEEE, Kyoto, Japan, 2003, pp. 439-442.
Miyake et al., “A Development of Micro Sheath Flow Chamber,” in Proceedings of the IEEE Micro Electro Mechanical Systems Workshop 1991, 265-270 (Jan. 1991).
Tashiro et al., “Design and Simulation of Particles and Biomolecules Handling Micro Flow Cells with Three-Dimensional Sheath Flow,” in Proceedings of the microTAS 2000 Symposium, 209-212 (May 14, 2000).
Weigl, B. et al. “Design and Rapid Prototyping of Thin-Film Laminate-Based Microfluidic Devices.” Biomedical Microdevices, 3:4, pp. 267-274, 2001.
Blankenstein, G. et al. “Modular concept of a laboratory on a chip for chemical and biochemical analysis.” Biosensors & Bioelectronics, vol. 13. No 3-4, pp. 427-438, 1998.
Shapiro, Practical Flow Cytometry, 15-17, 133-135 (3rd ed. 1995).
Shapiro, Practical Flow Cytometry, 55-57, 166-169 (4th ed. 2003).
International Search Report for PCT Patent Application No. PCT/IB2014/001425 dated Apr. 28, 2015.
Herweijer, H. et al., “High Speed Photodamage Cell Selection Using Bromodeoxyuridine/Hoechst 33342 Photosensitized Cell Killing”, Radiobiological Institute TNO, Rotterdam, The Netherlands, Jun. 1, 1987.
Johnson, L.A., et al., “Sex Preselection: High-Speed Flow Cytometric Sorting of X and Y Sperm for Maximum Efficiency” U.S. Dept. of Agriculture, Beltsville, MD, Sep. 23, 1999.
Bazyer H., et al., “Views and Reviews—Compact 151W Green Laser with U-Type Resonator for Prostate Surgery”, Optics & Laser Technology, vol. 47, Apr. 27, 2013, 237-241.
Keij, J. et al., “High-Speed Photodamage Cell Sorting: An Evaluation of the Zapper Prototype”, Methods in Cell Biology, 1994; pp. 371-386, vol. 42, Chapter 22, Academic Press, Inc.
International Search Report and Written Opinion dated Mar. 7, 2014 in connection with PCT/US2013/050669.
Kachel, V, et al., “Uniform Lateral Orientation, caused by Flow Forces, of Flat Particles in Flow-Through Systems”, The Journal of Histochemistry and Cytochemistry, vol. 25, No. 7, pp. 774-780, 1977.
Notice of Allowance issued in U.S. Appl. No. 13/943,322 dated Sep. 12, 2014.
Fulwler, M., “Hydrodynamic Orientation of Cells”, The Journal of Histochemistry and Cytochemistry, vol. 25, No. 7, pp. 781-783, 1977.
Khodjakov A., et al., “A Synergy of Technologies: Combining Laser Microsurgery with Green Fluorescent Protein Tagging”, Cell Motility and the Cytoskeleton 38:311-317 (1997), Division of Molecular Medicine and Department of Biomedical Sciences, Albany, New York.
Canadian Office Action, Application No. 2,929,275, dated May 4, 2020, 8 pages.
Australian Office Action, Application No. 2019202882, dated Mar. 26, 2020, 3 pages.
Brazilian Office Action, Application No. BR122017012966-0, dated Jun. 2, 2020, 6 pages.
Japan Patent Office, “Reconsideration Report by Examiner before Appeal,” issued in connection with Japanese Patent Application No. 2016-551082, dated Jul. 12, 2019, 17 pages. 20090114285.
Intellectual Property India, “Examination Report,” issued in connection with Indian Patent Application No. 3425/DELNP/2015, dated Jan. 20, 2020, 6 pages.
European Patent Office, “Extended European Search Report,” issued in connection with patent application No. 19182993.6, dated Oct. 21, 2019, 11 pages.
China National Intellectual Property Administration, “Second Office Action,” issued in connection with Chinese Patent Application No. 201480071952.0, dated Nov. 26, 2018, 34 pages.
China National Intellectual Property Administration, “Decision of Rejection,” issued in connection with Chinese Patent Application No. 201480071952.0, dated Mar. 4, 2019, 19 pages.
IP Australia, “Examination Report No. 1 for Standard Patent Application,” issued in connection with Australian Patent Application No. 2014343391, dated Sep. 4, 2018, 3 pages.
International Preliminary Report on Patentability, issued in connection with application PCT/IB/001425, dated May 3, 2016, 11 pages.
Japan Patent Office, “Non Final Notice of Reasons for Rejection,” issued in connection with Japanese Patent Application No. 2016-551082, dated Apr. 24, 2018, 5 pages.
New Zealand IP Office, “First Examination Report,” issued in connection with New Zealand Patent Application No. 720575, dated Sep. 9, 2016, 5 pages.
New Zealand IP Office, “Further Examination Report,” issued in connection with New Zealand Patent Application No. 720575, dated Apr. 28, 2017, 3 pages.
State Intellectual Property Office of People's Republic of China, “Notification of First Office Action,” issued in connection with Chinese Patent Application No. 201480071952.0, dated Mar. 16, 2018, 31 pages.
New Zealand IP Office, “Further Examination Report,” issued in connection with New Zealand Patent Application No. 735496, dated Aug. 31, 2018, 2 pages.
Drobnis et al., Cold Shock Damage is due to Lipid Phase Transitions in Cell Membranes: A Demonstration Using Sperm as a Model, The Journal of Experimental Zoology, 1993, 265:432-437.
Way et al., Comparison of four staining methods for evaluating acrosome status and viability of ejaculated and cauda epididymal bull spermatozoa, Theriogenology, 1995, 43(8): 1301-1316.
Marian et al., Hypo-osmotic Shock Induces an Osmolality-dependent Permeabilization and Structural Changes in the Membrane of Carp Sperm, 1993, 41(2):291-297.
Molecular Probes Inc., Product Information, Influx Pinocy1ic Cell-Loading Reagent (1-14402), Revised Feb. 1, 2001, 1-7.
Parks, Processing and Handling Bull Semen for Artificial Insemination—Don't Add Insult to Injury!, Department of Animal Sciences, Cornell University, 2001, retrieved on May 29, 2015, retrieved from the internet: http://www/ansci.cornell.edu/bullsemen.pdf.
Mammal (Online Datasheet), Wikipedia, 2003, retrieved on Aug. 13, 2018, retrieved from internet: http://web.archive.org/web/20031230110838/hllps://en.wikipedia.org/wiki/Mammal.
International Searching Authority, “International Search Report and Written Opinion,” issued in connection with International Patent Application No. PCT/IB2016/000295, dated Oct. 14, 2016, 19 pages.
International Bureau, “International Preliminary Report on Patentability,” issued in connection with International Patent Application No. PCT/IB2016/000295, dated Aug. 31, 2017, 14 pages.
Japan Patent Office, “Office Action,” issued in connection with Japanese Patent Application No. 2017-543990, dated Jul. 31, 2019, 23 pages.
Di Carlo et al. “Equilibrium Separation and Filtration of Particles Using Differential Inertial Focusing” Anal. Chem. 2008, 80, 2204-2211 (Year: 2008).
Hydraulic Diameter, Neutrium, Apr. 1, 2012, https://neutrium.net/fluid-flow/hydraulic-diameter/ (Year: 2012).
Gossett et al. “Particle Focusing Mechanisms in Curving Confined Flows” Anal. Chem. 2009, 81, 8459-8465 (Year: 2009).
Di Carlo et al. “Continuous inertial focusing, ordering, and separation of particles in microchannels” PNAS Nov. 27, 2007 vol. 104 No. 48 18893 (Year: 2007).
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 17/403,642, dated Nov. 29, 2021, 13 pages.
Intellectual Property India, “Examination Report,” issued in connection with Indian Patent Application No. 201917009874, dated Nov. 25, 2021, 6 pages.
Australian Office Action, Application No. 2017323502, dated Oct. 22, 2021, 6 pages.
Al-Holy et al., “The Use of Fourier Transform Infrared Spectroscopy to Differentiate Escherichia Coli O157:H7 from Other Bacteria Inoculated Into Apple Juice,” Food Microbiology, vol. 23, 2006, 162-168.
Alberts et al., “Molecular Biology of the Cell, 5th edition,” New York: Garland Science, 2008, p. 1293.
Barcot et al., “Investigation of Spermatozoa and Seminal Plasma by Fourier Transform Infrared Spectroscopy,” Applied Spectroscopy, vol. 61, No. 3, Mar. 2007, pp. 309-313.
Bassan et al; “Reflection Contributions to the Dispersion Artefact in FTIR Spectra of Single Biological Cells,” Analyst, vol. 134, Apr. 9, 2009, pp. 1171-1175.
Bassan et al; “Resonant Mie Scattering in Infrared Spectrascopy of Biological Materials-Understanding the Dispersion Artefact',” Analyst, vol. 134, 2009, pp. 1586-1593.
Bassan et al; “Resonant Mie Scattering {RMieS) Correction of Infrared Spectra From Highly Scattering Biological Samples,” Analyst, vol. 135, No. 2, Feb. 2010, pp. 268-277.
Belkin et al.; “Intra-Cavity Absorption Spectroscopy with Narrow-Ridge Microfluidic Quantum Cascade Lasers,”Applies Express, vol. 15, No. 18, Sep. 3, 2007, pp. 11262-11271.
Boustany et al.; “Microscopic Imaging and Spectroscopy with Scattered Light,” Annual Review of Biomedical Engineering, vol. 12, 2010, pp. 285-314.
Chan et al.; “Nondestructive Identification of Individual Leukemia Cells by Laser Trapping Raman Spectroscopy,” Analytical Chemistry, vol. 80, No. 6, Mar. 15, 2008, 8 pages.
Chan et al.; “Label-Free Biochemical Characterization of Stem Cells Using Vibrational Spectroscopy,” Journal of Biophotonics vol. 2, No. 11, Aug. 5, 2009, pp. 656-668.
Chan et al.; “Label-Free Separation of Human Embryonic Stem Cells {hESCs} and their Cardiac Derivatives using Raman Spectroscopy,” Lawrence Livermore Journal, LLNL-JRNL-406938, Sep. 11, 2008, 30 pages.
Chen et al,; “Synchrotron Infrared Measurements of Protein Phosphorylation in Living Single PC12 Cells during Neuronal Differentiation,” Analytical Chemistry, vol. 84, 2012, pp. 4118-4125.
Cheng et al., “Laser-Scanning Coherent Anti-Strokes Raman Scattering Microscopy and Applications to Cell Biology,” Biophysical Journal, vol. 83, Jul. 2002, pp. 502-509.
Cho et al., “Passively Driven Integrated Microfluidic System for Separation of Motile Sperm,” Analytical Chemistry, vol. 75, Apr. 1, 2003, Abstract.
Cho et al., A Microfluidic Device For Separating Motile Sperm From Nonmotile Sperm Via Inter-Streamline.
Cleary et al., “Infrared Surface Plasmon Resonance Biosensor,” OSA Biomed, Miami, Florida, Apr. 2010, 6 pages.
Dousseau et al., “On the Spectral Subtraction of Water from the FT-IR Spectra of Aqueous Solutions of Proteins,” Applied Spectroscopy, vol. 43, No. 3, 1989, pp. 538-542.
Downes et al., “Optical Spectroscopy for Noninvasive Monitoring of Stem Cell Differentation,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 101864, 2010, 10 pages.
Ege, “Organic Chemistry: Structure and Reactivity,” Fifth Edition, Boston, MA, Houghton Mifflin Company, 2004, pp. 453-457.
European Patent Office, “Extended European Search Report,” issued in connection with European Patent Application No. 11841869.8, dated Feb. 15, 2018, 9 pages.
Fu et al., “A Microfabricated Fluorescence-Activated Cell Sorter,” Nature Biotechnology, vol. 17, Nov. 1999, pp. 1109-1111.
Green et al., “Flow Cytometric Determination of Size and Complex Refractive Index for Marine Particles: Comparison with Independent and Bulk Estimates,” Applied Optics, vol. 42, No. 3, Jan. 20, 2003, pp. 526-541.
Harvey et al., “Discrimination of Prostate Cancer Cells by Reflection Mode FTIR Photoacoustic Spectroscopy,” The Analyst, vol. 132, 2007, pp. 292-295.
Herzenberg et al., “Fluorescence-activated Cell Sorting,” Scientific American, vol. 234, Mar. 1976, pp. 108-117.
Holman et al., “Synchrotron-Based FTIR Spectromicroscopy: Cytotoxicity and Heating Considerations,” Journal of Biological Physics, vol. 29, 2003, pp. 275-286.
Holman et al., “IR Spectroscopic Characteristics of Cell Cycle and Cell Death Probed by Synchrotron Radiation Based Fourier Transform IR Spectromicroscopy,” Biopolymers (Biospectroscopy) vol. 57, 2000, pp. 329-335.
Holman et al., “Tracking Chemical Changes in a Live Cell: Biomedical Applications of SR-FTIR Spectromicroscopy, ”Lawrence Berkeley National Laboratory, http://escholarship.org/uc/item/9k185794, Berkeley, CA Jul. 25, 2002, 34 pages.
Huser et al., “Raman Spectroscopy of DNA Packaging in Individual Human Sperm Cells Distinguishes Normal From Abnormal Cells,” Journal of Biophotonics, vol. 2, No. 5, 2009, pp. 322-332.
Intel, “Intel C-bank Tunable Laser, Performance and Design,” White Paper, May 2003, 14 pages.
International Searching Authority, “International Search Report and Written Opinion,” International Patent Application No. PCT/US2013/41123, dated Aug. 19, 2013, 12 pages.
International Search Authority, “International Preliminary Report on Patentability,” International Patent Application No. PCT/US2011/061046, dated May 30, 2013, 7 pages.
International Searching Authority, “International Preliminary Report on Patentability,” International Patent Application No. PCT/US2013/041123, dated Nov. 18, 2014, 7 pages.
Japan Patent Office, “Office Action,” issued in connection with Japanese Patent Application No. 2013-539983, dated Jul. 8, 2015, 6 pages.
Japan Patent Office, “Office Action,” issued in connection with Japanese Patent Application No. 2013-539983, dated Jul. 2, 2016, 6 pages.
Japan Patent Office, “Office Action,” issued in connection with Japanese Patent Application No. 2016-198323, dated Oct. 2, 2017, 3 pages.
Japan Patent Office, “Office Action,” issued in connection with Japanese Patent Application No. 2016-198323, dated Jul. 25, 2018, 9 pages.
Lee et al., “DFB Quantum Cascade Laser Arrays,” IEEE Journal of Quantum Electronics, vol. 45, No. 5, May 9, pp. 554-565.
Ibbus et al., “Incidence of Chromosome Aberrations in Mammalian Sperm Stained with Hoechst 33342 and UV- aser Irradiated During Flow Sorting,” Mutation Research, vol. 182, 1987, pp. 265-274.
Malone, Jr., “Infrared Microspectroscopy: A Study of the Single Isolated Bread Yeast Cell,” Thesis, The Ohio State University, 2010, 162 pages.
Meister et al., “Confocal Raman Microspectroscopy as an Analytical Tool to Assess the Mitochondral Status in Human Spermatozoa,” Analyst, vol. 135, 2010, pp. 1370-1374.
Miyamoto et al., “Label-free Detection and Classification of DNA by Surface Vibration Spectroscopy in Conjugation with Electrophoresis,” Applied Physics Letters, vol. 86, No. 053902, 2005, 3 pages.
Mohlenhoff et al., “Mie-Type Scattering and Non-Beer-Lambert Absorption Behavior of Human Cells in Infared Microspectroscopy,” Biophysical Journal, vol. 88, May 2005, pp. 3635-3640.
Montag et al., “Laser-induced Immobilization and Plasma Membrane Permeabilization in Human Spermatozoa,” Human Reproduction, vol. 15, No. 4, 2000, pp. 846-852.
Mourant et al., “Methods for Measuring the Infrared Spectra of Biological Cells,” Physics in Medicine and Biology, vol. 48, 2003, pp. 243-257.
Van Munster, “Interferometry in Flow to Sort Unstained X-and Y-Chromosome-Bearing Bull Spermatozoa,”Cytometry, vol. 47, 2002, pp. 192-199.
Rajagopalan et al., “Aneuploidy and Cancer,” Nature, vol. 432, Nov. 2004, pp. 338-341.
Ropcke et al., “Application of Mid-Infrared Tuneable Diode Laser Absorption Spectroscopy to Plasma Diagnostics: A Review,” Plasma Sources Science and Technology, vol. 15, 2006, S148-S168.
Schaden et al., “Quantum Cascade Laser Modulation for Correction of Matrix-Induced Background Changes in Aqueous Samples,” Applied Physics B, vol. 86, 2007, pp. 347-351.
Sandt et al., “Identification of Spectral Modifications Occurring during Reprogramming of Somatic Cells,” PLoS ONE, vol. 7, Issue 4, e30743, Apr. 2012, 7 pages.
Jokinen, Ville, et al. “Durable superhydrophobicity in embossed CYTOP fluoropolymer micro and nanostructures”, Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 434, 2013, pp. 207-212.
Forsberg, Pontus, Fredrik Nikolajeff, and Mikael Karlsson, “Cassie-Wenzel and Wenzel-Cassie transitions on immersed superhydrophobic surfaces under hydrostatic pressure”, Soft Matter, vol. 7, No. 1, 2011, pp. 104-109.
Lu, Hang, Martin A. Schmidt, and Klavs F. Jensen, “Photochemical reactions and on-line UV detection in microfabricated reactors”, Lab on a Chip, vol. 1, No. 1, 2001, pp. 22-28.
Japan Patent Office, “Office Action,” issued in connection with Japanese Patent Application No. 2019-513891, dated Jun. 24, 2021, 11 pages.
Brazilian Office Action, Application No. BR112019004727-1, dated Jul. 6, 2021, 4 pages.
Australian Office Action, Application No. 2017323502, dated Jun. 28, 2021, 6 pages.
China Office Action, Application No. 201780056064.5, dated Apr. 26, 2021, 8 pages.
China Office Action, Application No. 201780056064.5, dated Nov. 4, 2020 11 pages.
Europe Office Action, Application No. 17808998.3, dated Jul. 21, 2020.
Pedreira Carlos E et al.: “Overview of clinical flow cytometry data analysis: recent advances and future challenges”, Trends in Biotechnology, Elsevier Publications, Cambridge, GB, vol. 31, No. 7, Jun. 5, 2013.
China Patent Office, “The Third Office Action,” issued in connection with China Patent Application No. 201480071952.0, dated Jul. 23, 2020, 23 pages.
Intellectual Property India, “Examination Report,” issued in connection with Indian Patent Application No. 3429/DELNP/2015, dated Mar. 26, 2018, 6 pages.
European Patent Office, “ European Search Report,” issued in connection with patent application No. 20167363.9, dated Jul. 21, 2020, 9 pages.
Japan Patent Office, “Notice of Reasons for Refusal,” issued in connection with Japan Patent Application No. 2018-220397, dated Aug. 5, 2020, 3 pages.
European Patent Office, “Examination Report,” issued in connection with European Patent Application No. 16723498.8, dated Oct. 12, 2020, 6 pages.
European Patent Office, “European Search Report,” issued in connection with European Patent Application No. 14168200.5, dated Mar. 20, 2015, 12 pages.
European Patent Office, “European Search Report,” issued in connection with European Patent Application No. 17172322.4, dated Aug. 24, 2017, 8 pages.
European Patent Office, “European Search Report,” issued in connection with European Patent Application No. 15160613.4, dated Jul. 24, 2015, 14 pages.
European Patent Office, “Communication pursuant to Article 94(3) EPC,” issued in connection with European Patent Application No. 17172322.4, dated Aug. 14, 2018, 5 pages.
European Patent Office, “Communication pursuant to Article 94(3) EPC,” issued in connection with European Patent Application No. 11193936.9, dated Dec. 11, 2015, 3 pages.
European Patent Office, “Communication pursuant to Article 94(3) EPC,” issued in connection with European Patent Application No. 15160613.4, dated Jul. 11, 2016, 4 pages.
Hori et al., “Cell fusion by optical trapping with laser-involves contacting different cells with each other then imparting high voltage pulse to cells,” WPI/Thompson, Dec. 27, 1991, Abstract, 1 page.
Japan Patent Office, “Notification of Reasons for Refusal,” issued in connection with Japanese Patent Application No. 2016-185743, dated Jul. 3, 2018, 7 pages.
Japan Patent Office, “Final Notification of Reasons for Rejection,” issued in connection with Japanese Patent Application No. 2011-256171, dated Oct. 28, 2014, 5 pages.
Japan Patent Office, “Decision for Grant,” issued in connection with Japanese Patent Application No. 2015-091320, dated May 6, 2017, 7 pages.
Japan Patent Office, “Final Notification of Reasons for Rejection,” issued in connection with Japanese Patent Application No. 2015-091320, dated Mar. 22, 2016, 22 pages.
Japan Patent Office, “Notification of Reasons for Refusal,” issued in connection with Japanese Patent Application No. 2016-185743, dated Jul. 26, 2017, 2 pages.
Smith et al., “Inexpensive Optical Tweezers for Undergraduate Laboratories,” Am. J. Phys., vol. 67, No. 1, Jan. 1999, 10 pages.
Takayama et al., “Patterning Cells and Their Environments Using Multiple Laminar Fluid Flows in Capillary Networks,” Proceedings of National Academy of Sciences, vol. 96, 1999, 4 pages.
Ts'O, Basic Principles in Nucleic Acid Chemistry, National Library of Medicine, 1974, pp. 311-387.
Japan Patent Office; “Notice of Reasons for Refusal,”issued in connection with Japanese Patent Application No. 2019-088655, dated Feb. 18, 2020, 5 pages.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2013/050669, dated Jan. 28, 2016, 15 pages.
Supplementary European Search Report for U.S. Appl. No. 13/889,551, dated May 22, 2017, 12 pages.
State Intellectual Property Office of People's Republic of China, “Second Office Action,” issued in connection with Chinese Patent Application No. 201380079634.4, dated Jun. 4, 2018, 14 pages.
Japan Patent Office, “Notice of Reasons for Rejection,” issued in connection with Japanese Patent Application No. 2017-168904, dated Jul. 6, 2018, 3 pages.
State Intellectual Property Office of People's Republic of China, “Third Office Action,” issued in connection with Chinese Patent Application No. 201380079634.4, dated Nov. 1, 2018, 20 pages.
Japanese Office Action for Application No. 2016-527978 dated Mar. 28, 2017, 8 pages.
State Intellectual Property Office of People's Republic of China, “First Office Action,” issued in connection with Chinese Patent Application No. 201380079634.4, dated Jul. 28, 2017, 18 pages.
Indian Patent Application No. 3425/DELNP/2015 Pre-Grant Opposition, mailed Dec. 4, 2020, 138 pages.
Indian Patent Application No. 3425/DELNP/2015 Pre-Grant Opposition, mailed Jul. 21, 2020, 59 pages.
Indian Patent Application No. 3425/DELNP/2015 Pre-Grant Opposition, mailed Jul. 21, 2020, 96 pages.
Indian Patent Application No. 3425/DELNP/2015 Pre- Grant Opposition, mailed Jul. 2, 2020, 137 pages.
Sell, “Cellular Origin of Cancer: Dedifferentiation or Stem Cell Maturation Arrest?”, Environmental Health Perspectives, vol. 101, Suppl. 5, 1993, p. 15-26.
Shapiro et al., “Pratical Flow Cytometry,” Fourth Edition, New Jersey: John W. Wiley & Sons, 2003, 733 pages.
Sharpe et al., “Advances in Flow Cytometry for Sperm Sexing,” Theriogenology, vol. 71, 2009, pp. 4-10.
Short, “Raman Spectroscopy Detects Biochemical Changes Due to Proliferation in Mammalian Cell Cultures,” Biophysical Journal, vol. 88, Jun. 2005, pp. 4274-4288.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 15/226,899, dated Apr. 12, 2018, 14 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 15/226,899, dated Aug. 23, 2018, 5 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 15/226,899, dated Sep. 20, 2018, 6 pages.
USPTO, “Final Office Action,” issued in connection with U.S. Appl. No. 15/174,681, dated Jan. 2, 2018, 15 pages.
USPTO, “Final Office Action,” issued in connection with U.S. Appl. No. 15/174,681, dated Sep. 14, 2018, 17 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 15/174,681, dated May 4, 2017, 13 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 15/174,681, dated Apr. 5, 2018, 16 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 15/174,681, dated Nov. 27, 2018, 10 pages.
USPTO, “Final Office Action,” issued in connection with U.S. Appl. No. 13/298,148, dated Oct. 18, 2013, 46 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 13/298,148, dated Feb. 5, 2013, 66 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 13/298,148, dated Sep. 19, 2014, 9 pages.
USPTO, “Office Action,” issued in connection with U.S. Appl. No. 13/298,148, dated Sep. 28, 2012, 5 pages.
USPTO, “Final Office Action,” issued in connection with U.S. Appl. No. 13/894,831, dated Sep. 10, 2015, 11 pages.
USPTO, “Final Office Action,” issued in connection with U.S. Appl. No. 13/894,831, dated Jun. 15, 2017, 19 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 13/894,831, dated Dec. 23, 2014, 11 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 13/894,831, dated Oct. 5, 2016, 17 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 13/894,831, dated Apr. 1, 2016, 8 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 13/894,831, dated Sep. 5, 2017, 9 pages.
Wang et al., Detection of endogenous biomolecules in Barrett's esophagus by Fourier transform infrared spectroscopy, PNAS, vol. 104, No. 40, Oct. 2, 2007, p. 15864-15869.
Webster, Merriam, “Definition of “successive,” Merriam Webster's Online Dictionary, accessed at http://www.merriamwebster.com/dictionary/successive,” Jun. 18, 2013, 1 page.
Weida et al., “Quantum Cascade Laser Based Replacement for FTIR Microscopy,” http://www.daylightsolutions. :: om/assets/003/5308.pdf, accessed online Aug. 2, 2012, 7 pages.
International Bureau, “International Preliminary Report on Patentability,” issued in connection with International Patent Application No. PCT/IB2017/001289, dated Mar. 21, 2019, 12 pages.
International Search Report and Written Opinion for Application Serial No. PCT/IP2017/001289, dated Apr. 3, 2018, 21 pages.
Mehrnoush Malek et al: flowDensity: reproducing manual gating of flow cytometry data by automated density-based cell population identification11 , Bioinformatics., vol. 31, No. 4, Oct. 16, 2014 (Oct. 16, 2014), pp. 606-607.
International Search Report and Written Opinion for Application Serial No. PCT/IB2018/001641, dated Jun. 25, 2020 4 pages.
China Patent Office, “The Fourth Office Action,” issued in connection with China Patent Application No. 201480071952.0, dated Jan. 3, 2021, 25 pages.
Japan Patent Office, “Notice of Reasons for Refusal,” issued in connection with Japan Patent Application No. 2019-088655, dated Oct. 13, 2020, 5 pages.
Johnson LA et al., Flow sorting of X and Y chromosome-bearing spermatozoa into two populations, Gamete Research. Jan. 1987. 16(1):1-9. (Johnson 1987).
Paape et al., Flow Cytometry: A Versatile Tool for Studies on Cells From Domestic Animals, National Cytometry Symposium, Abstract Only, Dec. 14, 1997, https://www.ars.usda.gov/research/publications/publication/?seqNo115=86408.
Keij, J.F. et al., “High-Speed Photodamage Cell Selection Using a Frequency-Doubled Argon Ion Laser.” Cytometry 19 (1995): 209-216. (Keij 1995).
Keij, J.F., “Introduction to High-Speed Flow Sorting.” Flow and Image Cytometry. Series H: Cell Biology, 95 (1996): 213-227. (Keij 1996).
Johnson LA, Welch GR, Rens W. “The Beltsville sperm sexing technology: high-speed sperm sorting gives improved sperm output for in vitro fertilization and AI.” J Anim Sci 1999. 77:213-220.
Counterclaim Defendants ABS Global Inc.'s And Genus PLC's Invalidity Contentions. ABS Global, Inc., v. Inguran, LLC D/B/A Sexing Technologies and. XY, LLC v. Genus PLC. Case No. 14-cv-503 United States District Court for the Western District of Wisconsin; pp. 1, 43-114, and 168-177.
ABS Global, Inc. and Genus PLC's Renewed Motion for Judgment as a Matter of Law That the Asserted Claims of the '987 Patent Are Invalid for Lack of Enablement and, in the Alternative, for a New Trial. ABS Global, Inc. v. Inguran, LLC & XY, LLC v. Genus PLC. Case: 3:14-cv-00503-wmc. Filed on Jul. 3, 2020.
Brief in Support of ABS Global, Inc. and Genus PLC's Motion for Judgment as a Matter of Law That the Asserted Claims of the '987 Patent Are Not Enabled. Inguran, LLC d/b/a Stgenetics, XY, LLC, and Cytonome/ST, LLC, Plaintiffs/Counterclaim-Defendants, v. ABS Global, Inc., Genus PLC, and Premium Genetics (UK) LTD, Defendants/Counterclaim-Plaintiffs. Case: 3:17-cv-00446 wmc. Filed Sep. 6, 2019.
ABS Global, Inc. and Genus PLC Renewed Motion for Judgment as a Matter of Law That the Asserted Claims of the 987 Patent Are Invalid for Lack of Enablement and, in the Alternative, for a New Trial. Inguran, LLC d/b/a Stgenetics, XY, LLC, and Cytonome/ST, LLC, Plaintiffs/Counterclaim-Defendants, v. ABS Global, Inc., Benus PLC, and Premium Genetics (UK) LTD, Defendants/Counterclaim-Plaintiffs. Case: 3:17-cv-00446-wmc. filed Jul. 3, 2020.
ABS Global, Inc. and Genus PLC's Reply in Support of Their Renewed Motion for Judgment as a Matter of Law That the Asserted Claims of the '987 Patent Are Invalid for Lack of Enablement and, in the Alternative, for a New Trial. Inguran, LLC d/b/a Stgenetics, XY, LLC, and Cytonome/ST, LLC, Plaintiffs/Counterclaim-Defendants, v. ABS Global, Inc., Genus PLC, and Premium Genetics (UK) LTD, Defendants/Counterclaim-Plaintiffs. Case: :17-cv-00446-wmc. Filed Aug. 17, 2020.
ABS Global, Inc. and Genus PLC's Motion for Judgment as a Matter of Law That the Asserted Claims of the 987 and '092 Patents Are Invalid. ABS Global, Inc., Plaintiff/Counterclaim Defendant, v. Inguran, LLC d/b/a Sexing Technologies, Defendant/Counterclaim Plaintiff, and XY, LLC, Intervenor-Defendant/Counterclaim Plaintiff, v. Genus PLC, Counterclaim Defendant. Case: 3:14-cv-00503-wmc. Filed Aug. 9, 2016.
ABS Global, Inc. and Genus PLC's Rule 50(8) Motion for Judgment as a Matter of Law and Rule 59 Motion for a New Trial. ABS Global, Inc., Plaintiff/Counterclaim Defendant, v. Inguran, LLC d/b/a Sexing Technologies, Defendant/Counterclaim Plaintiff, and XY, LLC, Intervenor-Defendant/Counterclaim Plaintiff, V. Benus PLC, Counterclaim Defendant. Case: 3:14-cv-00503-wmc. Filed Sep. 2, 2016.
Opinion and Order of the United States District Court for the Western District of Wisconsin. Plaintiff/Counterclaim Defendant, v. Inguran, LLC d/b/a Sexing Technologies, Defendant/Counterclaim Plaintiff, and XY, LLC, Intervenor-Defendant/Counterclaim Plaintiff, v. Genus PLC, Counterclaim Defendant. Case: 3:14-cv-00503-wmc. filed Mar. 31, 2017.
Appeal from the United States District Court for the Western District of Wisconsin. No. 14-CV-503. ABS Global, NC., Plaintiff/Counterclaim Defendant-Appellant, and Genus PLC, Counterclaim Defendant-Appellant, v. Inguran, LLC, doing business as Sexing Technologies, Defendant/Counterclaim Plaintiff-Appellee, and XY, LLC, Intervening Defendant/Counterclaim Plaintiff-Appellee. Case: 3:14-cv-00503-wmc. Filed: Mar. 8, 2019.
Judge's Opinion & Order in Case No. 14-cv-503-wmc. Plaintiff/Counterclaim Defendant, v. Inguran, LLC dib/a Sexing Technologies, Defendant/Counterclaim Plaintiff, and XY, LLC, Intervenor-Defendant/Counterclaim Plaintiff, v. Genus PLC, Counterclaim Defendant. Case: 3:14-cv-00503-wmc. Filed Jul. 21, 2016.
ABS Global Inc. and Genus PLC's Reply in Support of Their Motion for Claim Construction and Partial Summary Judgment, ABS Global, Inc. v. Inguran, LLC d/b/a Sexing Technologies, Case No. 14-cv-503, United States District Court for the Western District of Wisconsin. Mar. 7, 2016.
Jun et al. “Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data.” The American Journal of Human Genetics 91.5 (2012): 839-848.
International Searching Authority, “International Search Report and Written Opinion,” issued in connection with International Patent Application No. PCT/US21/56094, dated Mar. 16, 2022, 22 pages.
China National Intellectual Property Administration, “Notice of Allowance,” issued in connection with Chinese Patent Application No. 201480071952.0, dated Mar. 21, 2022, 3 pages.
Australian Office Action, Application No. 2021200818, dated Mar. 4, 2022, 3 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 16/864,514, dated Jan. 3, 2022, 24 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 16/419,756, dated Jan. 12, 2022, 16 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 17/458,947, dated Dec. 15, 2021, 9 pages.
Di Carlo, “Inertial microfluidics.” Lab on a Chip 9.21 (2009): 3038-3046.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 16/741,608, dated Mar. 18, 2022, 12 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 17/412,789, dated Mar. 21, 2022, 30 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 17/458,947, dated Mar. 31, 2022, 30 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 17/496,469, dated May 10, 2022, 54 pages.
Intellectual Property India, “Examination Report,” issued in connection with Indian Patent Application No. 202147003036, dated Jan. 4, 2022, 5 pages.
China Patent Office, “The Fifth Office Action,” issued in connection with China Patent Application No. 2014800719520, dated Oct. 20, 2021, 7 pages.
Intellectual Property India, “Examination Report,” issued in connection with Indian Patent Application No. 202017054203, dated Jan. 7, 2022, 5 pages.
USPTO, “Final Office Action,” issued in connection with U.S. Appl. No. 17/403,642, dated Mar. 4, 2022, 14 pages.
Kang, et al. “Effect of an osmotic differential on the efficiency of gene transfer by electroporation of fish spermatozoa.” Aquaculture 173.1-4 (1999): 297-307. (Year: 1999).
Rieth et al. “Electroporation of bovine spermatozoa to carry DNA containing highly repetitive sequences into oocytes and detection of homologous recombination events.” Molecular Reproduction and Development: Incorporating Gamete Research 57.4 (2000): 338-345.
Chamberland et al. “The effect of heparin on motility parameters and protein phosphorylation during bovine sperm capacitation. ”Theriogenology 55.3 (2001): 823-835. (Year: 2001).
Chan, et al. “Luminescent quantum dots for multiplexed biological detection and imaging.” Current opinion in biotechnology 13.1 (2002): 40-46. (Year: 2002).
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 16/561,146, dated Jan. 21, 2022, 14 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 17/496,469, dated Jan. 28, 2022, 13 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 17/692,876, dated Sep. 19, 2022, 21 pages.
USPTO, “Notice of Allowance,” issued in connection with U.S. Appl. No. 17/403,642, dated Sep. 29, 2022, 24 pages.
USPTO, “Final Office Action,” issued in connection with U.S. Appl. No. 16/741,608, dated Jun. 13, 2022, 11 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 17/403,642, dated Jul. 13, 2022, 7 pages.
CNIPA, “First Office Action,” issued in connection with Chinese Patent Application No. 202080028183.1, dated Jul. 6, 2022, 21 pages.
New Zealand IP Office, “First Examination Report,” issued in connection with New Zealand Patent Application No. 751869, dated Aug. 12, 2022, 3 pages.
Canadian Office Action, Application No. 3,034,007, dated Aug. 25, 2022, 3 pages.
USPTO, “Final Office Action,” issued in connection with U.S. Appl. No. 16/741,608, dated Oct. 19, 2022, 12 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 17/851,319, dated Nov. 2, 2022, 12 pages.
USPTO, “Final Office Action,” issued in connection with U.S. Appl. No. 16/279,430, dated Dec. 6, 2022, 18 pages.
China National Intellectual Property Administration, “Second Office Action,” issued in connection with Chinese Patent Application No. 202080028183.1, dated Jan. 13, 2023, 23 pages.
European Patent Office, “European Search Report,” issued in connection with European Patent Application No. 22190948.4, dated Jan. 23, 2023, 10 pages.
European Patent Office, “Intention to Grant Notice,” issued in connection with patent application No. 20167363.9, dated Dec. 15, 2022, 8 pages.
Notice of Allowance issued in U.S. Appl. No. 17/851,319 dated Feb. 15, 2023, 52 pages.
European Patent Office, “European Search Report,” issued in connection with European Patent Application No. 20792020.8, dated Dec. 23, 2022, 10 pages.
Brazilian Office Action, Application No. BR112020023607-1, dated Dec. 12, 2022, 5 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 17/496,614, dated Dec. 21, 2022, 9 pages.
Ron Bardell et al. “Microfluidic disposables for cellular and chemical detection: CFD model results and fluidic verification experiments,” Proc. SPIE 4265, Biomedical Instrumentation Based on Micro- and Nanotechnology, May 21, 2001; doi: 10.1117/12.427961 Invited Paper: BiOS 2001 The International Symposium on Biomedical Optics, 2001, San Jose, CA, United States, 14 pages.
Notice of Allowance issued in U.S. Appl. No. 17/692,876 dated Feb. 1, 2023, 24 pages.
Notice of Allowance issued in U.S. Appl. No. 16/741,608 dated Feb. 7, 2023, 22 pages.
USPTO, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 17/164,710, dated Jun. 26, 2023, 13 pages.
National Institute of Industrial Property (INPI) Argentina, “Examination Report,” issued in connection with Argentina Patent Application No. 20190101378, dated Apr. 19, 2023, 8 pages.
China National Intellectual Property Administration, “Decision of Rejection,” issue in connection with Chinese Patent Application No. 202080028183.1, dated Jun. 7, 2023, 23 pages.
Brazilian Office Action, Application No. BR112021020390-7, dated Oct. 31, 2023, 4 pages.
Related Publications (1)
Number Date Country
20200329696 A1 Oct 2020 US
Provisional Applications (1)
Number Date Country
62835676 Apr 2019 US